JPH0443639B2 - - Google Patents
Info
- Publication number
- JPH0443639B2 JPH0443639B2 JP12958683A JP12958683A JPH0443639B2 JP H0443639 B2 JPH0443639 B2 JP H0443639B2 JP 12958683 A JP12958683 A JP 12958683A JP 12958683 A JP12958683 A JP 12958683A JP H0443639 B2 JPH0443639 B2 JP H0443639B2
- Authority
- JP
- Japan
- Prior art keywords
- enzyme
- substrate
- measuring
- denaturant
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 102000004190 Enzymes Human genes 0.000 claims description 123
- 108090000790 Enzymes Proteins 0.000 claims description 123
- 238000006243 chemical reaction Methods 0.000 claims description 98
- 239000000758 substrate Substances 0.000 claims description 65
- 238000011069 regeneration method Methods 0.000 claims description 64
- 230000008929 regeneration Effects 0.000 claims description 61
- 230000000694 effects Effects 0.000 claims description 40
- 239000003398 denaturant Substances 0.000 claims description 35
- 239000000126 substance Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 16
- 239000003446 ligand Substances 0.000 claims description 15
- 230000001172 regenerating effect Effects 0.000 claims description 15
- 239000007795 chemical reaction product Substances 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 12
- 230000008859 change Effects 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000005259 measurement Methods 0.000 description 53
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 26
- 238000006911 enzymatic reaction Methods 0.000 description 25
- 239000003112 inhibitor Substances 0.000 description 24
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 22
- 239000000376 reactant Substances 0.000 description 20
- 239000003153 chemical reaction reagent Substances 0.000 description 15
- 230000007423 decrease Effects 0.000 description 13
- 239000000047 product Substances 0.000 description 12
- 238000010799 enzyme reaction rate Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 239000002532 enzyme inhibitor Substances 0.000 description 9
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 8
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 8
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 8
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 7
- 230000003197 catalytic effect Effects 0.000 description 7
- 229960000485 methotrexate Drugs 0.000 description 7
- 229940125532 enzyme inhibitor Drugs 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 102000004316 Oxidoreductases Human genes 0.000 description 5
- 108090000854 Oxidoreductases Proteins 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 230000031700 light absorption Effects 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 238000010517 secondary reaction Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 150000005829 chemical entities Chemical class 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- NUFBIAUZAMHTSP-UHFFFAOYSA-N 3-(n-morpholino)-2-hydroxypropanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CN1CCOCC1 NUFBIAUZAMHTSP-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000009738 saturating Methods 0.000 description 3
- NBWRJAOOMGASJP-UHFFFAOYSA-N 2-(3,5-diphenyl-1h-tetrazol-1-ium-2-yl)-4,5-dimethyl-1,3-thiazole;bromide Chemical compound [Br-].S1C(C)=C(C)N=C1N1N(C=2C=CC=CC=2)N=C(C=2C=CC=CC=2)[NH2+]1 NBWRJAOOMGASJP-UHFFFAOYSA-N 0.000 description 2
- 230000003281 allosteric effect Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 238000007824 enzymatic assay Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- VFRROHXSMXFLSN-KCDKBNATSA-N aldehydo-D-galactose 6-phosphate Chemical group OP(=O)(O)OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O VFRROHXSMXFLSN-KCDKBNATSA-N 0.000 description 1
- 238000012801 analytical assay Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000011155 quantitative monitoring Methods 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000005460 tetrahydrofolate Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N βâMercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
ãçºæã®è©³çްãªèª¬æã
ïŒçºæã®åéïŒ
ãã®çºæã¯ã掻æ§é
µçŽ å€æ§å€ã®æž¬å®æ¹æ³åã³ã
ã®ããã®çµæç©ã«é¢ããã ïŒçºæã®èæ¯ïŒ é µçŽ ãšããŠç¥ãããçš®é¡ã®èçœè³ªã®æãæçšãª
æ§è³ªã¯ãããç¹å®ã®ååŠåå¿ãè§Šåªããèœåãæ
ããããšã§ãããããããŠå°ãªãäŸå€ãé€ããé µ
çŽ ã®ååšåã³æ¯æŽ»æ§ã¯ãåºè³ªãåå¿çæç©ã«è»¢æ
ããç¹å®ã®åå¿ã®ååšã«ããæž¬å®ããããå žåç
ã«ã¯ãåå¿ç³»ã«ååšããæŽ»æ§é µçŽ ã®éã¯ãåå¿é
床ãé µçŽ ã®æ¿åºŠã«ããéå®ãããæ¡ä»¶äžã§ã®åå¿
é床ã«ããæž¬å®ããããåå¿éåºŠã®æž¬å®ã¯ãé µçŽ
ã®çš®é¡åã³ãã®é µçŽ ã䜿çšããç¹å®ã®åå¿ç³»ã®ã
ããã«ããããããåæç枬å®ã®æãéèŠãªéšå
ãããããé µçŽ åå¿é床ã®äžæ£ç¢ºãªæž¬å®ã¯åžžã«æž¬
å®ã®æ£ç¢ºããšç²ŸåºŠã®äœäžãããããã åæçé µçŽ æž¬å®ã«ãããŠã¯ãé µçŽ ã®ç¹å®ã®æŽ»æ§
ãå€åããããæŽ»æ§å€æ§å€ã䜿çšããããšãæã
æç¢ºã«èšãã°ãåºè³ªã®çæç©ãžã®å€åã®é床ããª
ãã¡åå¿é床ãå€åããããããšãæçšã§ããã
ãã®ãããªæŽ»æ§é µçŽ å€æ§å€ã«ã¯ãå éå€ãããªã
ã¡é µçŽ åå¿ã®é床ãäžæããããããšãã§ããç©
質ãåã³æžéå€ãããªãã¡åå¿é床ãäœäžããã
ãç©è³ªãå«ãŸãããæžéå€ã®ç¯çã¯éåžžã«å€§ã
ããããã«ã¯é µçŽ é»å®³å€ãå«ãŸããããã¯å¯éç
é»å®³å€ãäžå¯éçé»å®³å€åã³ã¢ãã¹ããªãã¯å¹æ
å€ã«åãããããç¹å®ã®é µçŽ é»å®³å€ã®éã®æž¬å®ã¯
åœæ¥çã«ãããŠããç¥ãããŠãããäŸãã°ãã©ãŠ
ã³ïŒBrounïŒããžãšã³ãœã³ïŒJohnsonïŒããŠã€ãã
ïŒWitteïŒåã³ããšã«ãïŒFeldïŒã®ãEnzymatie
Inhibition Assay For Methorexate With 
Discrete AnalyzerïŒthe ABAâ100ãClinical
ChemistryïŒ26ïŒ355ã338ïŒ1980幎ïŒã®çºè¡šãã
ããäžèšã®çš®é¡ã®ããããã®ç¹ç°çé µçŽ é»å®³å€
ã¯ãç±³åœç¹èš±ç¬¬4134792å·ãè±åœç¹èš±ç¬¬1595101
å·ã䞊ã³ã«ç±³åœç¹èš±ç¬¬4273866å·åã³ç¬¬3935074å·
ã«èšèŒãããŠããå ç«æž¬å®æ³ã«ããäŸç€ºãããã
ãšãããªã¬ã³ãæ¥åé»å®³å€ã®åœ¢ã§éåžžã«è€éãªå
æç³»ã«ã䜿çšãããŠãããé µçŽ åå¿é床ã®å€åã®
æ£ç¢ºãªæž¬å®ã«äŸåããä»ã®åæ¥çã«äœ¿çšãåŸãç³»
ããããŒãŒã³ã¿ãŒã«ïŒRosenthalïŒçãClinical
ChemistryïŒ22ïŒ1899ïŒ1976幎ïŒã«èšèŒãããŠã
ãããã«ãEMITæ¹åŒã«ããäŸç€ºãããã é µçŽ åå¿ã®åååŠãçã«åå¿éåºŠã®æž¬å®åã³å
å¿é床ã«åãŒãçš®ã ã®é µçŽ æŽ»æ§å€æ§å€ã®åœ±é¿ã«ã€
ããŠã®çè«ãšå®éããã¬ãŒãã³ã¬ãŒ
ïŒLehningerïŒïŒBiochemistryïŒç¬¬ïŒçïŒWorth
Publishers瀟ã1975幎ã䞊ã³ã«ãã€ã¯ãœã³
ïŒDixonïŒåã³ãŠãšãïŒWebbïŒïŒEnzymesïŒ
Academic PressïŒ1979幎ã«ååã«èšèŒãããŠã
ãããã®çºæãååäžã€å®å šã«çè§£ããããã«ã¯
é µçŽ åååŠã®ååãªçè§£ãå¿ èŠã§ãããåŸæ¥æè¡
ã®ç¶æ ãéè€ããŠèšèŒããããšãé¿ãããããäž
èšã®åŒçšæç®ãåŒçšã«ãããã®æçŽ°æžã«çµã¿å ¥ã
ããäžèšã®æç®ã¯ãåŸè¿°ãããã®çºæã®äŸ¡å€ã
ãããããŠéèŠãªé²æ©ãèªèãããããŠçºæãã
ããã®åºç€åã³èæ¯ãšããŠåœ¹ç«ã€ã§ãããã ãã¹ãŠã®é µçŽ åå¿ã®äžè¬çãªç¹åŸŽã¯ãåºè³ªãç
æç©ã«è»¢æãããé µçŽ åå¿é床ãæéãšå ±ã«äœäž
ããããšã§ããããã®é床ã®äœäžã¯çš®ã ã®çç±ã«
ããããããã®çç±ã«ã¯ãåå¿çæç©ã®èç©ã«ã
ãè§Šåªé床ãäœäžããããšãåå¿çæç©æ¿åºŠã®äž
æã«åŸã€ãŠéåå¿ãããã«éèŠã«ãªãããšã枩床
åã¯PHã®å€åã«ããé µçŽ èªäœããªãããã®äžæŽ»æ§
åãåããããšãå«ãŸãããããããªãããé µçŽ
åå¿é床ã®äœäžã®æãå¯èœæ§ã®ããåå ã¯ãåå¿
ãå®çµã«è¿ããã«åŸã€ãŠåºè³ªæ¿åºŠãäœäžãããã
ã«åºè³ªã«ããé µçŽ ã®é£œåã®çšåºŠãäœäžããããšã§
ããããããã®çç±ã®ãããéåžžã®é µçŽ æ¿åºŠæž¬å®
æ³ã«ãããŠã¯ãé µçŽ åå¿ã®åºçºé床ã®ã¿ã枬å®ã
ããåå¿é床ãå€åããããäžèšã®çš®ã ã®åå ã
åå¿é床ã«åœ±é¿ãåãŒãããåŸã€ãŠåå¿é床ãé µ
çŽ æ¿åºŠã®ã¿ã«ãã€ãŠèŠå®ãããã®ã¯é µçŽ åå¿äžã®
æåã®æéã®ã¿ã§ãããããã«ãé µçŽ åå¿ã®åæ
éåºŠãæž¬å®ããããã«ã¯ãåå¿ã®æåã®æ®µéã«ã
ããåå¿äœåã¯çæç©ã®ããããã®æ¿åºŠå€åã瀺
ãå®éšããŒã¿ã®ã¿ãåŸãå¿ èŠããããããæž¬å®ç³»
ã«ãããŠçš®ã ã®é µçŽ æ¿åºŠã«ã€ããŠã®åæåå¿é床
ãéãããããŠãããã°ã©ãã«ããããããŠã枬
å®ãããé床ãšé µçŽ æ¿åºŠãšã®é¢ä¿ãç€ºãæšæºæ²ç·
ãæ±ããã°ãããçã«åå¿é床ãé µçŽ æ¿åºŠã«æ¯äŸ
ããã®ã§ããã°ãçŽç·ãåŸãããã§ãããããã
ããªãããå®éã«ãé µçŽ åå¿èªäœã«ããçããæž¬
å®åªäœã®çµæã®å€åã®ãããããªãã¡é µçŽ åå¿ã®
åååŠã®ããã«ãåèšã®çŽç·æ§ã¯ãé µçŽ æ¿åºŠãäœ
ãå Žåã®ã¿ããããŠçæéã«ãããŠã®ã¿ååšã
ãã åŸã€ãŠãäžè¬ã«ã峿 Œãªæéãçšãããããã
ãŠåºè³ªéå®ãããã«äŒŽãå Žåã«ã®ã¿åé床ã«åºã
æšæºæ²ç·ã«ããé µçŽ æ¿åºŠã®çã®æž¬å®å€ãåŸãããš
ãã§ãããããããªããããã°ãã°ãé»å®³å€åã¯
é»å®³å€ãæ¥åãããªã¬ã³ããçšããåæçé µçŽ æž¬
å®åã³å ç«æž¬å®ã«ãããŠã¯ããããã®æéåã³åº
質éå®ã®ãããããç¡èŠããããããŠè¶ éããŠã
ãããã®çµæããããã®å€ãã®é µçŽ æž¬å®ã¯æ£ç¢ºã§
ããªã粟å¯ã§ããªããããããªãããæéããã
ãé µçŽ åå¿éåºŠã®æž¬å®ã«ãããäžèšã®ãããªèª€å·®
ã¯ããã®çºæã«ããé€å»ãããåã¯å®è³ªçã«æžå°
ããã ãã®çºæã«ãããæŽ»æ§é µçŽ å€æ§å€ã®ååšã«ãã
掻æ§ãå€åããé µçŽ ïŒè©²é µçŽ ã«ããåå¿çæç©ã«
転åãããã®ã«é©ããåºè³ªïŒè©²é µçŽ ã«ãã該åºè³ª
ã®åå¿çæç©ãžã®è»¢æã«å¿ èŠãªã³ã»ãã¢ã¯ã¿ãŒïŒ
åã³é µçŽ åå¿çæç©ããå°ãªããšãïŒã€ã®åå¿äœ
ãåçããããã®ææ®µãå«ãã§æãæªç¥è©Šéšè©Šæ
äžã®æŽ»æ§é µçŽ å€æ§å€ã®éãæž¬å®ããããã®åæç
æž¬å®æ¹åŒãæäŸããããåçãããåå¿äœã¯åºè³ª
ã§ãã€ãŠããããã³ã»ãã¢ã¯ã¿ãŒã§ãã€ãŠãã
ããåãã®äž¡è ã§ãã€ãŠããããããã«ããã®å
çææ®µã«ãããåçã®çµæãšããŠåå¿äœã®ã»ãã«
å°ãªããšãïŒçš®ã®ä»ã®çæç©ãçæãããã該ä»
ã®çæç©ãã詊éšè©Šæäžã«ååšããæŽ»æ§é µçŽ å€æ§
å€ã®å®éçåã¯å®æ§ç枬å®ã«çšããããšãã§ã
ããåå¿äœãåçããææ®µã«ããé µçŽ åå¿é床ã
å®å®åããå®è³ªçãªæéã«ããã€ãŠåå¿éåºŠãæ¬
質äžäžå®ãšãªãã ïŒæ§æã®å ·äœçãªèª¬æïŒ ãã®æçŽ°æžã«ãããŠã¯äžèšã®å®çŸ©ãçšããã ãé µçŽ ãã¯ãåå¿äœãçæç©ã«è»¢æããããã«
æ©èœããè§Šåªéšäœãå°ãªããšãïŒã€æããä»»æã®
èçœè³ªã§ããã ãåå¿äœãã¯ãååŠåå¿ãåããä»»æã®ååŠçš®
ã§ããã ãçæç©ãã¯ãé µçŽ åå¿ãä»ããŠçæããä»»æ
ã®ååŠçååšã§ããã ãåºè³ªãã¯ãããã«å¯ŸããŠé µçŽ ãè§Šåªäœçšãå
ãŒãååŠçååšã§ããã ãã³ã»ãã¢ã¯ã¿ãŒãã¯ãè§ŠåªæŽ»æ§ã®ããã«é µçŽ
ã«å¿ èŠãªéå±ã€ãªã³åã¯ææ©ååããæãååŠç
ååšã§ãããå¿ èŠãªã³ã»ãã¢ã¯ã¿ãŒãé µçŽ ããé€
å»ãããå Žåãé µçŽ ã¯è§Šåªçã«äžæŽ»æ§ãšãªãã ãè£é µçŽ ãã¯ãé µçŽ ã®æ§é ã®ç¹å®ã®éšäœã«çµåã
ãææ©ååã³ã»ãã¢ã¯ã¿ãŒã§ãããè£é µçŽ ã¯ãå š
é µçŽ åå¿ã®éçšã§ç§»åããå®èœåºãç¹å®ã®ååå
ã¯é»åã®äžéæ äœãšããŠæ©èœããã ããªã¬ã³ããã¯ãä»ã®ååãšåå¿ããŠè€åäœã
圢æããä»»æã®ã€ãªã³åã¯ååã§ããã ãäžæ¬¡åå¿ãã¯ãïŒã€ã®åå¿äœã®æ¿åºŠã«çŽæ¥ç
ã«æ¯äŸããé床ã§é²è¡ããé µçŽ åå¿ã§ããã ãäºæ¬¡åå¿ãã¯ãïŒã€ã®åå¿äœã®æ¿åºŠã®ç©ïŒå
ã¯ïŒã€ã®åå¿äœã®æ¿åºŠã®ïŒä¹ïŒã«æ¯äŸããé床ã§
é²è¡ããé µçŽ åå¿ã§ããã ãé¶æ¬¡åå¿ãã¯ãåå¿äœã®æ¿åºŠä»¥å€ã®èŠå ã«ã
ãå€åããé床ã§é²è¡ããé µçŽ åå¿ã§ããããã®
åå¿ã¯éåžžãé µçŽ æ¿åºŠã«æ¯äŸããã ãæŽ»æ§é µçŽ ãã¯ãååšããé µçŽ ã®å šéã®å ãè§Š
åªçã«æ©èœçã§ããããããŠåºè³ªãçæç©ã«è»¢æ
ããããšãã§ããéšåã§ããã ãæŽ»æ§é µçŽ å€æ§å€ãã¯ãé µçŽ ãšçµåããŠé µçŽ æŽ»
æ§ã®åŒ·ããšæ§åŒãå€åããããä»»æã®ååŠçååš
ã§ããã倿§ã«ãããé µçŽ åå¿é床ã®äžæããã
ã¯äœäžãåºè³ªç¹ç°æ§ã®å€åãåã¯é µçŽ æŽ»æ§ã®å€å
ãããã¯é µçŽ æŽ»æ§ã®æ§åŒã®å€åã«ããæ€åºãåŸã
ç¹æ§ã®ä»ã®ä»»æã®å€åãçãããæŽ»æ§é µçŽ å€æ§å€
ã®å€§ããã¯ãå°ååãã巚倧ååãŸã§å€åãåŸ
ããæŽ»æ§é µçŽ å€æ§å€ãšé µçŽ ãšã®çžäºäœçšã¯ãäžé
ååäŒåã®åŒ·ãã«äŸåããŠå¯éçã§ããå Žåãã
ãäžå¯éçã§ããå Žåããããããªãã¡ãäžéå
åäŒåã匱ãå Žåã«ã¯æ¥éã«å¹³è¡¡ã«éããããäž
éååäŒåã匷ãå Žåã«ã¯å¹³è¡¡ã«éããåã¯é ã
平衡ã«éããã ãé µçŽ é»å®³å€ãã¯ãé µçŽ ãšã®çžäºäœçšã«ããé µ
çŽ ã®è§ŠåªæŽ»æ§ãäœäžããããæŽ»æ§é µçŽ å€æ§å€ã§ã
ããé»å®³å€ã®äœçšã®æ§åŒã¯æ®æçãéæ®æçãäž
æ®æçãã¢ãã¹ããªãã¯ãåã¯ãããã®æ§åŒã®çš®
çš®ã®çµåããã§ããã ãå埪ç°ç³»ãã¯ãåå¿çæç©ã«è»¢æãããåºè³ª
ã®éãæå€§ã«ããããã«ç¹ç°çé µçŽ åå¿ã®å®çµã
é§åããããã«ã®ã¿é µçŽ åå¿ã«ã³ã»ãã¢ã¯ã¿ãŒã
äŸçµŠããä»»æã®ååŠåå¿åã¯ååŠåå¿ç³»åã§ã
ãã ãåçææ®µãã¯ãé µçŽ åå¿ã«ããçæãããç
æç©ã®å°ãªããšãïŒçš®ããé µçŽ ã«ããåã³çæç©
ã«è»¢æãããã®ã«é©ããåå¿äœãšããŠåçããã
ãã«å¿ èŠãªåå¿äœãé µçŽ ãè§Šåªãåã³ååŠåå¿å
ã¯ååŠåå¿ç³»åã§ããã ãã®çºæã¯ãæªç¥ã®çµæãæãã詊éšè©Šæäžã®
é µçŽ ã®ååšåã³æ¿åºŠã枬å®ããããã«é µçŽ åå¿ã®
éåºŠãæž¬å®ããåæçæž¬å®æ¹åŒã®æ¹è¯ã«é¢ããã
å žåœ¢çã«ã¯ããã®åæç枬å®ç³»ã¯ãåºè³ªãã³ã»ã
ã¢ã¯ã¿ãŒåã³æŽ»æ§é µçŽ ãå«ãã§æãããã®é µçŽ ã«
ããåºè³ªã®çæç©ãžã®è§Šåªç転æã«ãããååšã
ãæŽ»æ§é µçŽ ã®éãæž¬å®ããããé µçŽ åå¿éåºŠãæ£
ç¢ºã«æž¬å®ããåŸããã®é床ããé µçŽ æ¿åºŠã«å¯ŸããŠ
é床ãããããããæšæºæ²ç·ãšçµã¿åããããã«
ããã詊éšè©Šæäžã«ååšããæŽ»æ§é µçŽ ã®éã®æ£ç¢º
äžã€é«ç²ŸåºŠã®æž¬å®å€ãåŸããããããå Žåã«ã¯ã
掻æ§é µçŽ ã®éã¯ã掻æ§é µçŽ å€æ§å€ã®ååšåã³åœ±é¿
ã«ããå€åãããæ±ããããå¯äžã®æ å ±ã§ããã
ããããªããã蚺æåã¯èšåºã®ããã®åæç枬å®
ç³»ã«ãããŠã¯ãæªç¥éã®æŽ»æ§é µçŽ å€æ§å€ã®ååšäž
ã§è§Šåªçæ©èœãç¶æããæŽ»æ§é µçŽ ã®éã®å€åãã
倿§å€ã®æ¿åºŠã®æž¬å®ã®ããã«æ±ãããããã®å€æ§
å€ã¯ãã°ãã°é µçŽ é»å®³å€ã§ããã ããç¥ãããŠããæŽ»æ§é µçŽ å€æ§å€ã¯ãå¯éçé µ
çŽ é»å®³å€ãã¡ãœãã¬ãã»ãŒãïŒmethotrexateïŒ
ã§ããããã®ãã®ã¯çã®æ²»çã«åºã䜿çšãããã
ãããã®ãã®ã®ååšã®æ£ç¢ºäžã€å®éçãªç£èŠãç¹
ã«å¿ èŠã«ãªã€ããã¡ãœãã¬ãã»ãŒãïŒåã¯ãã®é¡
äœã§ããã¢ãããããªã³ïŒã¯åãããããªã¬ã³ã
ïŒå žåçã«ã¯æåãæäœåã¯çæ³å€ïŒãšæ¥åãã
å Žåã詊éšè©Šæäžã®ä»ã®å¯Ÿå¿ãããªã¬ã³ãã®ç·æ¿
åºŠãæž¬å®ããã®ã«æçšã§ããããããã®æž¬å®æ³ã¯
ãã§ã«èšèŒãããŠããå床詳现ã«åŒçšããå¿ èŠã¯
ãªãããã®ããããã®çºæã®å¥œãŸããå ·äœçæ æ§
ã«ãããŠã¯ãé µçŽ ãžãããããªã¬ãŒãã¬ãã¯ã¿ãŒ
ãŒïŒdihydrofolate reductaseïŒïŒDHFRãšç¥ãïŒ
åã³å¯éçé µçŽ é»å®³å€ã¡ãœãã¬ãã»ãŒããçšãã
ïŒã€ã®ã¢ãã«ãšããŠã®åæç枬å®ç³»ã䜿çšããã
ãã®å ·äœçæ æ§ã«ãããŠã¯ãåŸæ¥ããé·æéã«ã
ããDHFRã®åå¿éåºŠãæ£ç¢ºã«æž¬å®ã§ãããã
ãŠåŸãããå®éšããŒã¿ã«ãããç¹ç°çãªãªã¬ã³ã
ã«çµåãåŸãå€ãã®ç°ãçš®é¡ã®ç©è³ªã®ååšåã³é
ãæ£ç¢ºã«æž¬å®ãããã ãžãããããªã¬ãŒãã¬ãã¯ã¿ãŒãŒïŒDHFRïŒ
ã®åæç枬å®ç³»ã¯ãDHFRã嫿ããæ°Žæº¶æ¶²ã
ãžãããããªã¬ãŒãïŒdihydrofolateïŒïŒFA2ãšç¥
ãïŒãéå åã³ã»ãã¢ã¯ã¿ãŒã§ãããã³ãã³ã¢ã
ãã¢ããã³ãžãã¯ã¬ãªãããã¹ããšãŒã
ïŒnicotinamide adenine dinuclectid phosphate
ïŒNADPHãšç¥ãïŒäžŠã³ã«ãã®æçŽ°æžã«èšèŒãã
çš®ã ã®å¡©åã³ç·©è¡å€ãå«ãã§æããDHFRã¯
NADPHã®ãã³ãã³ã¢ããã¢ããã³ãžãã¯ã¬ãª
ãããã¹ããšãŒãïŒNADPãšç¥ãïŒãžã®é žåãš
åæã«FH2ã®ããã©ãããããªã¬ãŒã
ïŒtetrahydrofolateïŒïŒTH4ãšç¥ãïŒãžã®éå ãè§Š
åªããããã®åå¿ãåå¿åœ¢åŒïŒïŒã«ç€ºãã FH2åã³NADPHã®ããããã¯ãããããä»ã®
é µçŽ çåæçæž¬å®æ³ã«ãããŠäžè¬ã«äœ¿çšããã
ã³ã»ãã¢ã¯ã¿ãŒãšããŠåœæ¥è ã«ããç¥ãããŠã
ããããããªããããã®çºæã®DHFR枬å®ã¢ã
ã«ç³»ã«ãããŠã¯ããããã®åå¿äœã®ããããäžæ¹
ãåºè³ªãšç§°ãã仿¹ãã³ã»ãã¢ã¯ã¿ãŒãšç§°ããã
DHFRåæã¢ãã«ç³»ã«ãããŠãååå¿äœã¯ãä»
æ¹ã®åå¿äœãšã¯ç¬ç«ããŠåçããããšãã§ããã
ããããªãããä»ã®é µçŽ çåæç枬å®ã«ãããŠ
ã¯ããããã®ç©è³ªã¯ãã®é žåååã¯éå åã«ãã
ãŠã第äžã«ãã³ã»ãã¢ã¯ã¿ãŒãšããŠæ©èœãããã®
ãšäºæ³ãããã åå¿åœ¢åŒïŒïŒã«ç€ºãããDHFRåå¿ãé²è¡
ããé床ã¯ã340ããã¡ãŒãã«ïŒnmãšç¥ãïŒã«ã
ããåå¿æº¶æ¶²ã®å åžåã®æžå°ã芳å¯ãïŒãããŠèš
é²ããïŒããšã«ããæž¬å®ããããFH2åã³
NADPHã®äž¡è ã¯ãè©Šéšæ¿åºŠã«ãããŠã340nmã«
ãããŠã»ãšãã©åæ§ã«å ãåžåãããåå¿çæç©
ã§ããFH4åã³NADPã¯ããã®æ³¢é·ã«ãããŠå
ãåžåããªãã DHFR枬å®ã«ãããåå¿é床ã¯ã枬å®ç³»ã«å
åšããè§Šåªçã«æŽ»æ§ãªDHFRã®éã«ããéå®ã
ãããåå¿é床ã¯ã340nmã«ãããå åžåã®çµæ
çæžå°ã«ãã瀺ãããåºè³ªã®è»¢æã®åéåºŠãæž¬å®
ããããšã«ããæ±ºå®ããããåžåã®æžå°é床ãã
枬å®ã«ãããæŽ»æ§DHFRæ¿åºŠã«æ¯äŸããããã®
æ¹æ³ãçšããŠåå¿éåºŠãæ£ç¢ºã«æž¬å®ããããã«
ã¯ãFH2åã³NADPHã®äž¡è ãæåããååšãã
ãããŠDHFRã飜åããã®ã«ååé«ãæ¿åºŠãã
ãªãã¡é µçŽ ã«ååšããè§Šåªéšäœãåå¿ã®ãã¹ãŠã®
æç¹ã«ãããŠåºè³ªã«ããååã«æ¯é ãããŠããã®
ã«ååãªæ¿åºŠã«é£ç¶çã«ç¶æãããããšãå¿ èŠã§
ãããããããªãããåºè³ªåã³ã³ã»ãã¢ã¯ã¿ãŒã®
äž¡è ãšã340nmã«ãããŠå ãåžåããã®ã§ã枬å®
ã«ãããŠãããã®åå¿äœãããã«å€ã䜿çšããã
ã«ã€ããŠã¯å®éäžã®éçããããå ·äœçã«ã¯ãå
å¿äœã340nmã«ãããŠé«ãåžåã瀺ããããããª
ããæž¬å®äžDHFRã®éãšã®é¢é£ã«ãããŠé£œåæ¿
床ãç¶æããªããã°ãªããªããšããïŒã€ã®èŠè«ã®
ããã«ãDHFRãçãæ¿åºŠç¯å²ã§ã®ã¿äœ¿çšãã
ããšãã§ããããŠãã®å Žåã«ã®ã¿æ£ç¢ºãªæž¬å®ãã§
ããã äžèšã®èŠè«ãæºãããªãå Žåã®å¹æã瀺ãã
ããæž¬å®ã«ãã©ãŠã³ïŒBrownïŒçïŒClin.Chem.
26ïŒ355ïŒ1980幎ïŒã®è©Šè¬é åãçšãããè©Šè¬æ
åã®é åæ¿åºŠã第ïŒè¡šã«ç€ºãã 第ïŒè¡š è©Šè¬æå æ¿ 床 FH2 0.085mM NHDPH 0.104mM âã¡ã«ã«ãããšã¿ããŒã« 14.3ÎŒM çé žãããªãŠã 192mM ããªã¹ç·©è¡æ¶² 1.6mM çè¡æž ã¢ã«ããã³ 0.2ïŒ PH 6.5 DHFRã®æ¿åºŠãå€ãããã¹ãŠã®è©Šè¬ã¯äžå®ã«
ããé µçŽ åå¿é床ãçš®ã ã®æç¹ã§æž¬å®ãããå ·äœ
çã«ã¯ãïŒmlã®ãã©ãŠã³ã®è©Šè¬ã30âã«ãŠã€ã³ã
ãŠããŒããããããŠçš®ã ã®æ¿åºŠã®DHFR溶液20ÎŒ
ãå ããããšã«ããé µçŽ åå¿ãéå§ããã
DHFRã®æŽ»æ§åäœãïŒåéã«ïŒãã€ã¯ãã¢ã«ã®
FH2ã®éå ãè§Šåªããé µçŽ ã®éãšããŠå®çŸ©ããã
340nmã«ãããïŒåéåœãã®å åžåã®å€åããïŒ
åéééã§10åéã«ãããæž¬å®ããããšã«ããå
å¿é床ãç£èŠããããã®çµæã第ïŒå³ã®ã°ã©ãã«
瀺ãã 第ïŒå³ã®åæã«ããã°ããã©ãŠã³ã®è©Šè¬é åã«
ãããŠã¯ãDHFRã®æ¿åºŠãéåžžã«äœãå Žåã«ã®
ã¿æéã«é¢ããŠäžå®ã®é µçŽ åå¿é床ãåŸãããã
第ïŒå³ã¯ããã«ãåå¿åœ¢åŒïŒïŒããäž¡åå¿äœã
ããªãã¡åºè³ªïŒFH2ïŒåã³ã³ã»ãã¢ã¯ã¿ãŒ
ïŒNADPHïŒãå¶åŸ¡å åãšãªãäºæ¬¡åå¿ã§ããã
ãšã瀺ããŠãããåŸã€ãŠãåç®äžäžå®ã®åå¿é床
ãåŸãããã«ãããåºè³ªåã³ã³ã»ãã¢ã¯ã¿ãŒã®æ¿
床ãå®è³ªäžé«ãããªããã°ãªãããåã¯PHFRã®
éãäœãæ¿åºŠã«çšéããªããã°ãªããªãã 第ïŒå³ã«ç€ºããããŒã¿ãããã«ããããããäž
çŸ€ã®æ²ç·ãšããŠç¬¬ïŒå³ã«ãããããããåæ²ç·
ã¯ãç°ãæç¹ãç°ãé µçŽ æ¿åºŠã«ãããåå¿é床ã
ããªãŠãããïŒããªãªããã«ïŒmUïŒmlïŒãšããŠ
瀺ãããã®ã§ãããïŒæ¬ã®å®ç·ã¯ã10mUïŒmlæª
æºã®é µçŽ æ¿åºŠã«ãããŠæåã®ïŒåéã«åŸãããé
床ããŒã¿ã倿¿ãããã®ã§ãããDHFRã®èгå¯
ãããåå¿é床ã¯ãé µçŽ æ¿åºŠã®äžæã«åŸã€ãŠå®ç·
ããåçã«ããã¯ãªããããšãæããã§ãããã
ãã«ãåå¿é床ãæåã®ïŒåéã«æž¬å®ããå Žåã§
ãããDHFRæ¿åºŠãé«ããªãã«åŸã€ãŠè¥å¹²éçŽ
ç·çã«ãªãããããŠãããã®DHFRæ¿åºŠã«ãã
ãŠããçŽç·æ§ããã®åå·®ã¯ãåå¿æéãé·ããªã
ã«åŸã€ãŠã ãã ã倧ãããªãããšãæããã§ã
ãã éççãªããŒã¿ãã°ã©ãã«ããããããããã«
çŽç·ãé©çšããããšã«ãã€ãŠèŠããäžåççãªçŽ
ç·ãåŸãããããããã©ãŠã³ã®è©Šè¬é åãçšãã
DHFR枬å®ã«ãããåå¿é床ã®éçŽç·æ§ã¯ãäž
泚æãªèгå¯è ã«ãšã€ãŠã¯æããã§ã¯ãªããåå¿ã®
åæéåºŠãæž¬å®ããæ¡ä»¶äžã§ã®çŽç·æ§ããã®å€§ã
ãªåå·®ã¯ãéåžžãææ³ã®å·®ãåºè³ªã®æ¶è²»åã³çæ
ç©ã«ãããã€ãŒãããã¯é»å®³ã®ããã§ãããšã
ããåŸã€ãŠç¡èŠãããŠããŸããããããªããã第
ïŒå³åã³ç¬¬ïŒå³ã«ç€ºãããããŒã¿ãæ³šææ·±ã芳å¯
ããã°ããã©ãŠã³ã®è©Šè¬ã«ããæž¬å®ã¯ãäœãåºè³ª
æ¿åºŠã«ãããŠå®æœããå Žåã«ã®ã¿åç®äžçŽç·çã§
ããããšãæãããšãªããæã倧ããªèª€å·®åã³å
å·®ã¯ã掻æ§é µçŽ å€æ§å€ãåã¯æŽ»æ§é µçŽ å€æ§å€ã®ãª
ã¬ã³ãæ¥åç©ãšçµåãåŸãç©è³ªã®ååšã枬å®ãã
ããã®é µçŽ æž¬å®ã«ãããŠé«æ¿åºŠã®DHFRã䜿çš
ãããããšã«äŒŽã€ãŠçããã ãã©ãŠã³ã®è©Šè¬ãçšããæž¬å®ç³»ã«ãããæ¬ ç¹ã
èªèããäžã§ãé µçŽ æž¬å®ã«ãããŠã芳å¯ãããå
å¿é床ã®å®è³ªäžæ¹è¯ãããçŽç·æ§ãäŸãããã®çº
æã®ïŒã€ã®æ æ§ãåå¿åœ¢åŒïŒïŒã«ç€ºãã ãã®åå¿ã«ãããŠã¯ãDHFR枬å®ç³»ã«é µçŽ ã°
ã«ã³ãŒã¹âïŒâãã¹ããšãŒãããããã²ããŒãŒ
ïŒG6PDHïŒãå«ããæåã®äœ¿çšæ¿åºŠã第ïŒè¡šã«
瀺ãã 第ïŒè¡š è©Šè¬æå æ¿ 床 FH2 0.12mM NADPH 0.065mM âïŒâ 3.3mM G6PDH 1UïŒml ããªã¹ç·©è¡æ¶² 114mM MOPSOç·©è¡æ¶² 80mM ãžããªãšãªã¹ãªããŒã« 6mM PH 7.0 ãã®è¿œå ã®é µçŽ ã®ããã®åºè³ªã¯ã°ã«ã³ãŒã¹âïŒ
âãã¹ããšãŒãïŒG6PïŒã§ããããã®åºè³ªã¯ãã«
ã¿âïŒâãã¹ãã°ã«ã³ãã©ã¯ãã³ïŒÎŽâ6PGïŒã«
転æããããG6PDHåã³ïŒ§âïŒâã¯äžç·ã«ãª
ã€ãŠãDHFRé µçŽ åå¿ã«ããå ç«ã€ãŠçæãã
NADPããã®NADPHã®åçææ®µãæ§é ããã
ãã®NADPHåçææ®µãããã«äžè¬çã«ã³ã»ã
ã¢ã¯ã¿ãŒåçææ®µãšç§°ããã DHFR枬å®ç³»ã«å¯Ÿããã³ã»ãã¢ã¯ã¿ãŒåçæ
段ã®å¹æãã°ã©ãã«ããããããŠç¬¬ïŒå³åã³ç¬¬ïŒ
å³ã«ç€ºãããã®ããŒã¿ã¯æ¬¡ã®ããã«ããŠåŸãã
ããïŒmlã®è©Šè¬ã37âã«ãŠã€ã³ããŠããŒãããã
ããŠ0.0ã40mUïŒmlã®çš®ã ã®æ¿åºŠã«çšéãã
DHFR溶液20ÎŒãå ããããšã«ããé µçŽ åå¿ã
éå§ããã340nmã«ãããå åžåã®ïŒåéåœãã
ã®å€åãïŒåéééã§10åéã«ãããæž¬å®ããã
ãšã«ããåå¿é床ãç£èŠããã 第ïŒå³ã®ããŒã¿ãããNADPHåçææ®µã¯ã
é«ãDHFRæ¿åºŠã«ãããŠã10åéã®è©Šéšæéã«
ããã€ãŠå®è³ªäžäžå®ã®é µçŽ åå¿é床ãäŸããããš
ãæããã§ããã第ïŒå³ã®ããŒã¿ã第ïŒå³ã«åã
ããããããŠããããã®ç¬¬ïŒå³ã«ããã40mUïŒ
mlã®DHFRæ¿åºŠã«ãããŠãããã³ã»ãã¢ã¯ã¿ãŒ
åçææ®µãçŽç·æ§ãé¡èã«æ¹è¯ããããšã瀺ãã
ããå®ç·ã§ç€ºãããçŽç·ã¯ãåå¿ã®ç¬¬ïŒã®ïŒåé
ã®éã«æž¬å®ãããé床ããŒã¿ã倿¿ããŠåŸããã®
ã§ãããåå¿æéäžã®æåã®ïŒåéã®åŸã«ãããŠ
ã®ã¿DHFRåå¿é床ãæåã®åå¿é床ãããã
å§ããã芳å¯ããããããã®åå·®ã®æ·±å»ããã第
ïŒå³ã«ç€ºããããã©ãŠã³ã®è©Šè¬ã®å Žåã®ããã«æ¯
ã¹ãŠçžå¯Ÿçã«å°ããããšã¯ç¢ºå®ã§ãããDHFR
枬å®ç³»ã«ã³ã»ãã¢ã¯ã¿ãŒåçææ®µãå«ããããšã«
ããå šäœç广ã¯ãDHFRäºæ¬¡åå¿ãã
NADPHããã¯ãé žçŽ åå¿é床ãå¶åŸ¡ãåã¯ã
ãã«åœ±é¿ãäžããèŠçŽ ã§ã¯ãªãäžæ¬¡åå¿ã«å€ãã
ç¹ã«ããã DHFRåå¿ç³»ã«ã¡ãœãã¬ãã»ãŒãã®ããšã掻
æ§é µçŽ å€æ§å€ãå«ããå Žåã«ã¯è¿œå ã®è€éããç
ããã第ïŒã«ãã¡ãœãã¬ãã»ãŒãã«ããDHFR
ã®é»å®³ã¯å³æã«çããã®ã§ãªããDHFRåå¿é
床ã®èšé²ãåŸãé»å®³ãçããã®ã«å ç«ã€ãŠèгå¯ã
åŸãã©ã°æéãçããã第ïŒã«ãé»å®³å€ã«ããã©
ã°æéãèªå°ããããããDHFRåå¿é床ãå»¶
é·ãããæéã«ããã€ãŠããããåååŠçæ¡ä»¶äž
ã§æž¬å®ããå¿ èŠãããããããã®æž¬å®ææ®µã¯ãå
èšã®DHFRåå¿ã®åææ®µéã«ããããããšéåžž
ã«ç°ãªãããã®ãããªå€åããæ æ³ã«ãããå šäœ
çãªå¹æã¯ãDHFRæ¿åºŠãäžå®ã«ããé»å®³å€ã®
æ¿åºŠãã ãã ãé«ãããå Žåã®DHFRåå¿é床
ã®çŽç·æ§ãæ¯èŒããããšã«ãã瀺ãããããã®æ¯
èŒãã第ïŒè¡šã«ç€ºãè©Šè¬æåãçšããåå¿åœ¢åŒ
ïŒïŒã«ç€ºããã³ã»ãã¢ã¯ã¿ãŒåçææ®µã䜿çšã
ãŠãåã¯äœ¿çšããªãã§è¡ã€ãããã¹ãŠã®å Žåã«ã
ããŠDHFRã®éãåºå®ãããããŠG6PDHã¯èšèŒ
ããéã ã䜿çšãåã¯å šã䜿çšããªãã€ããæ¯èŒ
ã®çµæã第ïŒïŒïŒåã³ïŒå³ã«ç€ºãã 第ïŒè¡š è©Šè¬æå æ¿ 床 FH2 0.12mM NADPH 0.065mM âïŒâ 3.3mM G6PDH 1UïŒmlåã¯ç¡ã ããªã¹ç·©è¡æ¶² 114mM MOPSOç·©è¡æ¶² 80mM ãžããªãšãªã¹ãªããŒã« 6mM PH 7.0 MTXâDPH ïŒã10-6ïŒ ç¬¬ïŒå³ã¯ãDHFRåå¿ã®èгå¯ãããåå¿é床
ããçš®ã ã®æ¿åºŠã®æŽ»æ§é µçŽ é»å®³å€ã®ååšäžã§ã
ã³ã»ãã¢ã¯ã¿ãŒåçææ®µã䌎ã€ãŠåã¯äŒŽããªã
ã§ãé·æéã«ããã€ãŠæ¯èŒãããã®ã§ããã第ïŒ
衚ã«ç€ºãè©Šè¬æåïŒmlã37âã«ãŠã€ã³ããŠããŒã
ãããããŠ1UïŒmlã®DHFR溶液20ÎŒãå ããã
ãšã«ããåå¿ãéå§ããã340nmã«ãããå åžå
ã®ïŒåéåœãã®å€åãïŒåéééã§10åéã«ãã
ãæž¬å®ããããšã«ããåå¿é床ãç£èŠãããããŒ
ã¿ãåäžæ¡ä»¶äžã§åŸããäœããäžçµã®æž¬å®ã«ãã
ãŠã¯NADPHåçææ®µãçšãïŒå®ç·ã®æ²ç·ã§ç€º
ãïŒãä»ã®äžçµã®æž¬å®ã«ãããŠã¯ïŒ§âïŒâPDHæ
åãçšããªãã€ãïŒç Žç·ã®æ²ç·ã§ç€ºãïŒããã¹ãŠ
ã®æž¬å®æ··åç©ã«ã¯äžå®éã®DHFRãšçš®ã ç°ãªã
æ¿åºŠã®DHFRé»å®³å€ã嫿ããããããã®ç ç©¶
ã«ãããŠã¯ãé»å®³å€ãšããŠã¡ãœãã¬ãã»ãŒãã®ãª
ã¬ã³ãæ¥åäœãããªãã¡æçæ£å€ã§ãããžããšã
ã«ããã³ãã€ã³ã®å ç«æž¬å®ã«äœ¿çšãããγâïŒïŒïŒ
ïŒâãžããšãã«ããã³ãã€ã³âïŒâã¢ã»ãããã©
ãžãïŒâã¡ãœãã¬ãã»ãŒãïŒMTXâDPHïŒã䜿
çšãããMTXâDPHã¯ã(a)ïŒã(b)ïŒÃ10-8ïŒã
(c)ïŒÃ10-8ïŒã(d)ïŒÃ10-7ïŒã(e)ïŒÃ10-7ïŒåã³
(f)ïŒÃ10-6ïŒã®è©Šéšæ¿åºŠã§æ·»å ããã äžè¬ã«ã第ïŒå³ã第ïŒå³ãããé»å®³å€ã®æ¿åºŠã
å¢å ããã«åŸã€ãŠæž¬å®ãåŸãDHFR掻æ§ãäœäž
ããããšãããããããããªããã第ïŒå³ã®ããŒ
ã¿ã¯ãã³ã»ãã¢ã¯ã¿ãŒåçææ®µãçšããªã
DHFRæž¬å®æ³ã«ãããŠã¯ãé»å®³å€ã§ããMTXâ
DPHã®åè©Šéšæ¿åºŠã«ã€ããŠåå¿é床ãç°ãªããã
ããããã®åå¿é床ã¯é£ç¶çã«äœäžããããšã瀺
ããŠããã åŸã€ãŠããã®é»å®³å€ãããæªç¥ã®æ¿åºŠã§å«æã
ãïŒã€ã®è©Šéšè©Šæãããåºç¯å²ã«ç°ãªãDHFR
åå¿é床ãå®éšçã«æ±ãããããã®ããããã®å
å¿é床ã«ããïŒã€ã®è©Šéšè©Šæã«ã€ããŠç°ãªã
MTXâDPHæ¿åºŠã瀺ãããããšãæããã§ã
ããããã«å¯ŸããŠãDHFR枬å®ã«ã³ã»ãã¢ã¯ã¿
ãŒåçææ®µãçµåãããå Žåã«ã®ã¿èгå¯ãããå
å¿é床ãäžå®ãšãªãããããŠïŒåéã«ãããåŸé
ãé¶ã«ãªãã DHFR掻æ§ã¯é»å®³å€ã®æ¿åºŠã«åæ¯äŸãããšäº
æ³ããããããé»å®³å€ã®æ¿åºŠã®éæ°ã«å¯ŸããŠ
DHFRåå¿é床ãããããããã°ã©ãã¯å®è³ªäž
çŽç·ã«ãªãããšãäºæ³ãããã第ïŒå³åã³ç¬¬ïŒå³
ã«ããªã¬ã³ãã«æ¥åããé»å®³å€ã®ååšäžã§ã
NADPHã®ããã®ã³ã»ãã¢ã¯ã¿ãŒåçææ®µãçš
ãåã¯çšããªãå Žåã«ãããDHFR枬å®ã®çŽç·
æ§ã«å¯Ÿããåå¿æéã®åœ±é¿ã瀺ãã第ïŒå³ã«ç€ºã
ããŒã¿ã¯ç¬¬ïŒå³ã®ç Žç·ãšåãã§ããããé床ã
MTXâDPHæ¿åºŠã®éæ°ã®é¢æ°ãšããŠããããã
ãŠãããåæ²ç·ã¯ãå³ã«ç€ºãããæç¹ã§éåºŠãæž¬
å®ããå Žåã®çŽç·æ§ã«å¯Ÿå¿ããæçã«ããããïŒ
åéééã§ç€ºããŠãããçšããMTXâDPHã®æ¿
床ã¯ããããïŒÃ10-8ïŒãïŒÃ10-7ïŒãïŒÃ10-7
ïŒãïŒÃ10-6ïŒãåã³ïŒÃ10-6ïŒã§ããã 第ïŒå³ãããã³ã»ãã¢ã¯ã¿ãŒåçææ®µãçšããª
ãDHFR枬å®ã«ãããŠã¯ãæéã«åŸã€ãŠå€§ãã
å€åããäžçŸ€ã®é床å¿çæ²ç·ãåŸãããããšãæ
ããã§ãããããã«å¯ŸããŠãDHFR枬å®ã«ã³ã»
ãã¢ã¯ã¿ãŒåçææ®µãçšããå Žåã第ïŒå³ã«ç€ºã
ããã«ãDHFRé»å®³ã®çšåºŠã¯åççã«äžå®ã«ç¶
æããããããŠé»å®³å€ã®çšããããæ¿åºŠç¯å²ã«ã
ããŠåçŸæ§ãããã第ïŒå³ã®ããŒã¿ã¯ç¬¬ïŒå³ã®å®
ç·ã®æ²ç·ããåã€ããã®ã§ãããäœããé床ã
MTXâDPHæ¿åºŠã®éæ°ã®é¢æ°ãšããŠããããã
ããã®ã§ããã DHFR枬å®ç³»ã«ãããŠã³ã»ãã¢ã¯ã¿ãŒåçæ
段ã«ãã€ãŠäŸãããæãåçãªæ¹è¯ã¯ïŒã€ã®é
åãããªãã¡é»å®³å€ã®æ¿åºŠãæ¯èŒçé«ãåå¿é床
ãäœãå Žåãåã³é·æéã«ããã€ãŠé»å®³å€ã®æ¿åºŠ
ãéåžžã«äœãå Žåã§ãããæŽ»æ§é µçŽ å€æ§å€ã®ååš
äžã§ã®é床å¿çæ²ç·ã®çŽç·æ§ãã³ã»ãã¢ã¯ã¿ãŒå
çç³»ã«ããåçã«æ¹è¯ãããçç±ã¯ãã³ã»ãã¢ã¯
ã¿ãŒåçç³»ã«ãããäºååçãªäºæ¬¡åå¿ãäžåå
çãªäžæ¬¡åå¿ã«å¹æçã«å€åããããšã§ãããã
ã®ããšã¯NADPHã®æ¿åºŠããNADPHã«ã€ããŠ
ã®DHFRã®Kmå€ããé«ãäžå®ã®å€ã«ç¶æããã
ããšã«ããéæãããã ãã®çºæã®å¥œãŸããæ æ§ã«ãããŠã¯ãããã©ãŸ
ãªãŠã è²çŽ ïŒâïŒïŒïŒïŒâãžã¡ãã«ãã¢ãŸãŒã«â
ïŒâã€ã«ïŒâïŒïŒïŒâãžããšãã«â2Hâããã©ãŸ
ãªãŠã ããããïŒMTTïŒãDHFRã«ããçæã
ãFH2ã®FH2ãžã®åçãšéé µçŽ çã«å ±åœ¹ãã
DHFR枬å®ç³»ã®ããã®åºè³ªåçææ®µãçšããã
ãã®åºè³ªåçææ®µãåå¿åœ¢åŒïŒïŒã«èšèŒããã åºè³ªåçææ®µã¯ããã©ãŸãªãŠã è²çŽ MTTãã
æãããã®ãã®ã¯FH4ãFH2ã«è»¢æããããã«
ã³ã»ãã¢ã¯ã¿ãŒåçææ®µåã³åèšã®DHFR枬å®
ã«å ãããããåååŠçã«ã¯ãDHFRã«ãã
FH4ãçæããã«åŸãMTTãFH4ãšçµåãã
FH2ãåçãããšåæã«å¯çç©ãšããŠã¬ãããã«
ãã¶ã³è²çŽ ãçæãããã¬ãããã«ãã¶ã³è²çŽ ã¯
340nmã§ã¯ãªã568nmã«ãããŠã®ã¿å ãåžåã
ããåŸã€ãŠãFH2ã®åçã«äŒŽã€ãŠãFH4ã®FH2ãž
ã®ã¢ã«âã¢ã«è»¢æã瀺ã568nmã«ãããå åžåã®
å¢å ã芳å¯ããããDHFR枬å®ç³»ã«ãããŠãã®
åºè³ªåçææ®µãã³ã»ãã¢ã¯ã¿ãŒåçææ®µãšçµåã
ããŠäœ¿çšããå Žåãåçåå¿ã®ãã®çµåããã«ã
ããæåäºæ¬¡åå¿ã§ãã€ãåå¿ãé¶æ¬¡åå¿ã«å€ã
ããããã«äŒŽã€ãŠãDHFR枬å®ã«ãããé µçŽ å
å¿é床ã®çŽç·æ§ãããã«å®è³ªçã«å¢å ããã é床ã®çŽç·æ§ã®è¿œå ã®å¢å ã第ïŒå³ã®ã°ã©ãã«
瀺ãããã®ã°ã©ãã«ãããŠã¯ãé µçŽ é»å®³å€MTX
âDPHã®ååšäžã«ãããåºè³ªåçææ®µã®ã¿ã䜿
çšããDHFR枬å®ãšåºè³ªåçææ®µãšã³ã»ãã¢ã¯
ã¿ãŒåçææ®µãçµåãããŠäœ¿çšããDHFR枬å®
ãšãæ¯èŒãããŠããã åå¿æåã第ïŒè¡šã«ç€ºãã 第ïŒè¡š åå¿æå æ¿ 床 FH2 0.4mM NADPH 0.065mM MTT 0.12mM âïŒâ âŠ3.3mM G6PDHã 1UïŒmlïœåã¯ç¡ã ããªã¹ 114mM MOPSO 80mM DTE ïŒ PH 7.0 MTXâDPH ïŒã10-6ïŒ äžèšã®é»å®³è©Šè¬ïŒmlã37âã«ãããŠã€ã³ããŠã
ãŒããããããŠãDHFRã®ã¹ããã¯æº¶æ¶²ïŒ1UïŒ
mlïŒ20ÎŒãå ããããšã«ããé»å®³åå¿ãéå§ã
ããåå¿é床ã568nmã«ãããå åžåã®å€åãïŒ
åéééã§10åéã«ãããç£èŠããã ãã®æž¬å®ã®çµæãäžé£ã®æ²ç·ãšããŠç¬¬ïŒå³ã«ã°
ã©ããšããŠç€ºããå®ç·ã®æ²ç·ã¯NADPHåçæ
段åã³FH2åçææ®µã®äž¡æ¹ã®å¹æãéãªã€ãå Žå
ã瀺ããç Žç·ã®æ²ç·ã¯G6PDHãçšããªãFH2å
çææ®µã®ã¿ã®å¹æã瀺ããé»å®³å€MTXâDPHã®
è©Šéšæ¿åºŠã¯æ¬¡ã®éããšãããããªãã¡(a)ïŒã(b)ïŒ
Ã10-8ïŒã(c)ïŒÃ10-8ïŒã(d)ïŒÃ10-7ïŒã(e)ïŒÃ
10-7ïŒïŒåã³(f)ïŒÃ10-6ïŒã§ããã第ïŒå³ããã
åºè³ªåçææ®µåã³ã³ã»ãã¢ã¯ã¿ãŒåæææ®µãçµå
ãããŠäœ¿çšããDHFRåæç枬å®ã«ãããŠãé»
害å€ã®è©Šéšããã»ãšãã©å šæ¿åºŠç¯å²ã«ããããã
ããŠ10åéãè¶ ããå šè©Šéšæéã«ãããã
DHFRåå¿é床ã®çŽç·æ§ãåŸãããããšã容æ
ã«çè§£ã§ãããæããã«ãçŽç·æ§ã®è¿œå ã®å¢å
ã¯ãã³ã»ãã¢ã¯ã¿ãŒåçææ®µã䌎ãå Žåãš
DHFR枬å®ç³»ã®ã¿ãæ¯èŒãã第ïŒå³ã«ãããå Ž
åãšåæ§ã«åçã§ããã åå¿æ¹åŒïŒïŒã®åºè³ªåçææ®µã®å¹æãããã«
æç¢ºã«ç€ºãããã«ã第ïŒå³ã®ããŒã¿ã第ïŒå³åã³
第ïŒïŒå³ã«ãããŠã°ã©ããšããŠåããããããã 第ïŒå³ã¯ãMTXâDPHã®ååšäžã§FH2ã®ãã
ã®åºè³ªåçææ®µã®ã¿ãçšããDHFR枬å®ã®çŽç·
æ§ã«åãŒãæéã®åœ±é¿ã瀺ãããã®ããŒã¿ã¯ç¬¬ïŒ
å³ã«ãããç Žç·ã®æ²ç·ã®ããŒã¿ãšåãã§ãããäœ
ããé床ãé»å®³å€ã®æ¿åºŠã®éæ°ã®é¢æ°ãšããŠãã
ããããŠããã第ïŒå³äžã®åæ²ç·ã¯ãã°ã©ãã«è¡š
瀺ããæç¹ã§éåºŠãæž¬å®ããå Žåã«åŸãããçŽç·
æ§ã«å¯Ÿå¿ãããå®éã«äœ¿çšããMTXâDPHã®æ¿
床ã¯ïŒÃ10-8ïŒãïŒÃ10-7ïŒãïŒÃ10-7ïŒãïŒÃ
10-6ïŒãåã³ïŒÃ10-6ïŒã§ããã 第ïŒïŒå³ã¯ãFH2åã³NADPHã®ããã®äž¡åç
ææ®µãååšããå Žåã«åŸãããDHFRâé»å®³å€
枬å®ã®ããã«æ¹è¯ãããçŽç·æ§ã瀺ããããŒã¿ã¯
第ïŒå³ã®å®ç·ã®æ²ç·ãšåãã§ãããäœããé床ã
MTXâDPHæ¿åºŠã®éæ°ã®é¢æ°ãšããŠããããã
ãŠãããæž¬å®æéåã³é»å®³å€ã®æ¿åºŠã¯ç¬¬ïŒå³ã®å Ž
åã®ãããšåãã§ããã 第ïŒå³ãšç¬¬ïŒïŒå³ã®æ¯èŒããæãããªéããåº
質åçææ®µåã³ã³ã»ãã¢ã¯ã¿ãŒåçææ®µã®äž¡æ¹ã
çšããå Žåãé»å®³ãããDHFR枬å®ç³»ã«ããã
çŽç·æ§ã®ããã¯éåžžã«å°ãããªããå®éšç枬å®ã®
ç²ŸåºŠãæ¹è¯ãããã第ïŒå³ã«ãããããŒã¿ã«ãã
瀺ãããçŽç·æ§ããã®åå·®ã¯ãåºè³ªã§ããFH2ã®
é£œåæ¿åºŠã§ã®ååšäžã§ã³ã»ãã¢ã¯ã¿ãŒã§ãã
NADPHãæ¶è²»ãããããšã«èµ·å ãããšä¿¡ãã
ããããã®ããŒã¿ã¯ãåæ§ã®è©Šéšæ¡ä»¶ã®äžã§ã
ã³ã»ãã¢ã¯ã¿ãŒã§ããNADPHã®é£œåæ¿åºŠã§ã®
ååšäžã§ã®åºè³ªã§ããFH2ã®æ¶è²»ã®å¹æã瀺ã第
ïŒå³ã®ããŒã¿ãšé©åã«å¯Ÿæ¯ããããé床ã®çŽç·æ§
ããã®åå·®ã®çšåºŠãåäžã§ãªãããšãæããã§ã
ãããã®ããã«å¹æãç°ãã®ã¯ãé µçŽ ã§ãã
DHFRãšåºè³ªã§ããFH2ãšã®éã®Kmã«ãã€ãŠæž¬
å®ãããçµåèŠªåæ§ãšãDHFRãšã³ã»ãã¢ã¯ã¿
ãŒã§ããNADPHãšã®éã®çµåèŠªåæ§ãšã®çžç°
ã«ãããã®ãšä¿¡ãããããåçµåèŠªåæ§ã«ããã
å·®ç°ã䞊ã³ã«ç¬¬ïŒå³åã³ç¬¬ïŒå³ã®ããŒã¿ã¯ã枬å®
ç³»ã«ãããŠãé µçŽ DHFRã¯NADPHãšããã
FH2ãšãã匷ãçµåããããšãæããã«ç€ºããŠã
ãããã®èгå¯ã¯ãç ç©¶è ãåå¿é床ã®çŽç·æ§ãæ¹
è¯ããããã«ã³ã»ãã¢ã¯ã¿ãŒåçææ®µåã¯åºè³ªå
çææ®µã®ïŒæ¹ã®ã¿ã®äœ¿çšãéžæããªããã°ãªããª
ãç¶æ³ã«ãããŠç¹ã«æçšã«ãªãã ãã®çºæã®å¥œãŸããæ æ§ããDHFRãçšãã
åæç枬å®ç³»ã«é¢ããŠèª¬æããããã³ã»ãã¢ã¯ã¿
ãŒåã³ïŒåã¯åºè³ªãåçããããã®ææ®µãçšãã
ããšã«ãããäžè¬çã«ããããé µçŽ æž¬å®ç³»ã«ãã
ãŠåå¿é床ã®çŽç·æ§ãå®è³ªçã«æ¹è¯ããããšãã§
ãããããã®ãããªåçææ®µãçšããããšã«ã
ããçšããé µçŽ ç³»ã®ãããã«ããããããåžžã«ã
äžå±€åäžäžã€äžè²«ããé µçŽ è§Šåªã®åå¿é床ãåŸã
ããããåçã«æé©ãªãã®ã¯åžžã«å¿ é æåãšèã
ãããæ¯èŒçå°æ°ã®ã³ã»ãã¢ã¯ã¿ãŒã§ãããã³ã»
ãã¢ã¯ã¿åçææ®µã奜ãŸããåçææ®µã§ãããé
床ã®çŽç·æ§ã®åäžã䌎ã€ãŠä»ã®å€ãã®é µçŽ ç³»ã®äž
éšãšããŠåçããããšãã§ããã³ã»ãã¢ã¯ã¿ãŒã
第ïŒè¡šã«åæãããäœããããã«éå®ããããã®
ã§ã¯ãªãã ã衚ã ã衚ã åã¯ãã«ããã
åº
åæ§ã«ãä»ã®åæçé µçŽ æž¬å®ç³»ã«ãããŠãåç
ææ®µã䜿çšããããšã«ããäºæ¬¡åå¿ç³»ãäžæ¬¡åå¿
ç³»ã«å€ãããããã«å¯Ÿå¿ããŠæž¬å®ãåŸãé床ã®çŽ
ç·æ§åã³åçŸæ§ãé«ãããããDHFR枬å®ä»¥å€
ã®é µçŽ ç³»ã«ãããåå¿äœã®åçã®ããã®ç¹ç°çå
çææ®µããåãªãäŸãšããŠç¬¬ïŒè¡šã«ç€ºãã ã衚ã ãã³
ã¯ã¬ã¢ãã³ãããŒãŒ
ã®ããã®çµæç©ã«é¢ããã ïŒçºæã®èæ¯ïŒ é µçŽ ãšããŠç¥ãããçš®é¡ã®èçœè³ªã®æãæçšãª
æ§è³ªã¯ãããç¹å®ã®ååŠåå¿ãè§Šåªããèœåãæ
ããããšã§ãããããããŠå°ãªãäŸå€ãé€ããé µ
çŽ ã®ååšåã³æ¯æŽ»æ§ã¯ãåºè³ªãåå¿çæç©ã«è»¢æ
ããç¹å®ã®åå¿ã®ååšã«ããæž¬å®ããããå žåç
ã«ã¯ãåå¿ç³»ã«ååšããæŽ»æ§é µçŽ ã®éã¯ãåå¿é
床ãé µçŽ ã®æ¿åºŠã«ããéå®ãããæ¡ä»¶äžã§ã®åå¿
é床ã«ããæž¬å®ããããåå¿éåºŠã®æž¬å®ã¯ãé µçŽ
ã®çš®é¡åã³ãã®é µçŽ ã䜿çšããç¹å®ã®åå¿ç³»ã®ã
ããã«ããããããåæç枬å®ã®æãéèŠãªéšå
ãããããé µçŽ åå¿é床ã®äžæ£ç¢ºãªæž¬å®ã¯åžžã«æž¬
å®ã®æ£ç¢ºããšç²ŸåºŠã®äœäžãããããã åæçé µçŽ æž¬å®ã«ãããŠã¯ãé µçŽ ã®ç¹å®ã®æŽ»æ§
ãå€åããããæŽ»æ§å€æ§å€ã䜿çšããããšãæã
æç¢ºã«èšãã°ãåºè³ªã®çæç©ãžã®å€åã®é床ããª
ãã¡åå¿é床ãå€åããããããšãæçšã§ããã
ãã®ãããªæŽ»æ§é µçŽ å€æ§å€ã«ã¯ãå éå€ãããªã
ã¡é µçŽ åå¿ã®é床ãäžæããããããšãã§ããç©
質ãåã³æžéå€ãããªãã¡åå¿é床ãäœäžããã
ãç©è³ªãå«ãŸãããæžéå€ã®ç¯çã¯éåžžã«å€§ã
ããããã«ã¯é µçŽ é»å®³å€ãå«ãŸããããã¯å¯éç
é»å®³å€ãäžå¯éçé»å®³å€åã³ã¢ãã¹ããªãã¯å¹æ
å€ã«åãããããç¹å®ã®é µçŽ é»å®³å€ã®éã®æž¬å®ã¯
åœæ¥çã«ãããŠããç¥ãããŠãããäŸãã°ãã©ãŠ
ã³ïŒBrounïŒããžãšã³ãœã³ïŒJohnsonïŒããŠã€ãã
ïŒWitteïŒåã³ããšã«ãïŒFeldïŒã®ãEnzymatie
Inhibition Assay For Methorexate With 
Discrete AnalyzerïŒthe ABAâ100ãClinical
ChemistryïŒ26ïŒ355ã338ïŒ1980幎ïŒã®çºè¡šãã
ããäžèšã®çš®é¡ã®ããããã®ç¹ç°çé µçŽ é»å®³å€
ã¯ãç±³åœç¹èš±ç¬¬4134792å·ãè±åœç¹èš±ç¬¬1595101
å·ã䞊ã³ã«ç±³åœç¹èš±ç¬¬4273866å·åã³ç¬¬3935074å·
ã«èšèŒãããŠããå ç«æž¬å®æ³ã«ããäŸç€ºãããã
ãšãããªã¬ã³ãæ¥åé»å®³å€ã®åœ¢ã§éåžžã«è€éãªå
æç³»ã«ã䜿çšãããŠãããé µçŽ åå¿é床ã®å€åã®
æ£ç¢ºãªæž¬å®ã«äŸåããä»ã®åæ¥çã«äœ¿çšãåŸãç³»
ããããŒãŒã³ã¿ãŒã«ïŒRosenthalïŒçãClinical
ChemistryïŒ22ïŒ1899ïŒ1976幎ïŒã«èšèŒãããŠã
ãããã«ãEMITæ¹åŒã«ããäŸç€ºãããã é µçŽ åå¿ã®åååŠãçã«åå¿éåºŠã®æž¬å®åã³å
å¿é床ã«åãŒãçš®ã ã®é µçŽ æŽ»æ§å€æ§å€ã®åœ±é¿ã«ã€
ããŠã®çè«ãšå®éããã¬ãŒãã³ã¬ãŒ
ïŒLehningerïŒïŒBiochemistryïŒç¬¬ïŒçïŒWorth
Publishers瀟ã1975幎ã䞊ã³ã«ãã€ã¯ãœã³
ïŒDixonïŒåã³ãŠãšãïŒWebbïŒïŒEnzymesïŒ
Academic PressïŒ1979幎ã«ååã«èšèŒãããŠã
ãããã®çºæãååäžã€å®å šã«çè§£ããããã«ã¯
é µçŽ åååŠã®ååãªçè§£ãå¿ èŠã§ãããåŸæ¥æè¡
ã®ç¶æ ãéè€ããŠèšèŒããããšãé¿ãããããäž
èšã®åŒçšæç®ãåŒçšã«ãããã®æçŽ°æžã«çµã¿å ¥ã
ããäžèšã®æç®ã¯ãåŸè¿°ãããã®çºæã®äŸ¡å€ã
ãããããŠéèŠãªé²æ©ãèªèãããããŠçºæãã
ããã®åºç€åã³èæ¯ãšããŠåœ¹ç«ã€ã§ãããã ãã¹ãŠã®é µçŽ åå¿ã®äžè¬çãªç¹åŸŽã¯ãåºè³ªãç
æç©ã«è»¢æãããé µçŽ åå¿é床ãæéãšå ±ã«äœäž
ããããšã§ããããã®é床ã®äœäžã¯çš®ã ã®çç±ã«
ããããããã®çç±ã«ã¯ãåå¿çæç©ã®èç©ã«ã
ãè§Šåªé床ãäœäžããããšãåå¿çæç©æ¿åºŠã®äž
æã«åŸã€ãŠéåå¿ãããã«éèŠã«ãªãããšã枩床
åã¯PHã®å€åã«ããé µçŽ èªäœããªãããã®äžæŽ»æ§
åãåããããšãå«ãŸãããããããªãããé µçŽ
åå¿é床ã®äœäžã®æãå¯èœæ§ã®ããåå ã¯ãåå¿
ãå®çµã«è¿ããã«åŸã€ãŠåºè³ªæ¿åºŠãäœäžãããã
ã«åºè³ªã«ããé µçŽ ã®é£œåã®çšåºŠãäœäžããããšã§
ããããããã®çç±ã®ãããéåžžã®é µçŽ æ¿åºŠæž¬å®
æ³ã«ãããŠã¯ãé µçŽ åå¿ã®åºçºé床ã®ã¿ã枬å®ã
ããåå¿é床ãå€åããããäžèšã®çš®ã ã®åå ã
åå¿é床ã«åœ±é¿ãåãŒãããåŸã€ãŠåå¿é床ãé µ
çŽ æ¿åºŠã®ã¿ã«ãã€ãŠèŠå®ãããã®ã¯é µçŽ åå¿äžã®
æåã®æéã®ã¿ã§ãããããã«ãé µçŽ åå¿ã®åæ
éåºŠãæž¬å®ããããã«ã¯ãåå¿ã®æåã®æ®µéã«ã
ããåå¿äœåã¯çæç©ã®ããããã®æ¿åºŠå€åã瀺
ãå®éšããŒã¿ã®ã¿ãåŸãå¿ èŠããããããæž¬å®ç³»
ã«ãããŠçš®ã ã®é µçŽ æ¿åºŠã«ã€ããŠã®åæåå¿é床
ãéãããããŠãããã°ã©ãã«ããããããŠã枬
å®ãããé床ãšé µçŽ æ¿åºŠãšã®é¢ä¿ãç€ºãæšæºæ²ç·
ãæ±ããã°ãããçã«åå¿é床ãé µçŽ æ¿åºŠã«æ¯äŸ
ããã®ã§ããã°ãçŽç·ãåŸãããã§ãããããã
ããªãããå®éã«ãé µçŽ åå¿èªäœã«ããçããæž¬
å®åªäœã®çµæã®å€åã®ãããããªãã¡é µçŽ åå¿ã®
åååŠã®ããã«ãåèšã®çŽç·æ§ã¯ãé µçŽ æ¿åºŠãäœ
ãå Žåã®ã¿ããããŠçæéã«ãããŠã®ã¿ååšã
ãã åŸã€ãŠãäžè¬ã«ã峿 Œãªæéãçšãããããã
ãŠåºè³ªéå®ãããã«äŒŽãå Žåã«ã®ã¿åé床ã«åºã
æšæºæ²ç·ã«ããé µçŽ æ¿åºŠã®çã®æž¬å®å€ãåŸãããš
ãã§ãããããããªããããã°ãã°ãé»å®³å€åã¯
é»å®³å€ãæ¥åãããªã¬ã³ããçšããåæçé µçŽ æž¬
å®åã³å ç«æž¬å®ã«ãããŠã¯ããããã®æéåã³åº
質éå®ã®ãããããç¡èŠããããããŠè¶ éããŠã
ãããã®çµæããããã®å€ãã®é µçŽ æž¬å®ã¯æ£ç¢ºã§
ããªã粟å¯ã§ããªããããããªãããæéããã
ãé µçŽ åå¿éåºŠã®æž¬å®ã«ãããäžèšã®ãããªèª€å·®
ã¯ããã®çºæã«ããé€å»ãããåã¯å®è³ªçã«æžå°
ããã ãã®çºæã«ãããæŽ»æ§é µçŽ å€æ§å€ã®ååšã«ãã
掻æ§ãå€åããé µçŽ ïŒè©²é µçŽ ã«ããåå¿çæç©ã«
転åãããã®ã«é©ããåºè³ªïŒè©²é µçŽ ã«ãã該åºè³ª
ã®åå¿çæç©ãžã®è»¢æã«å¿ èŠãªã³ã»ãã¢ã¯ã¿ãŒïŒ
åã³é µçŽ åå¿çæç©ããå°ãªããšãïŒã€ã®åå¿äœ
ãåçããããã®ææ®µãå«ãã§æãæªç¥è©Šéšè©Šæ
äžã®æŽ»æ§é µçŽ å€æ§å€ã®éãæž¬å®ããããã®åæç
æž¬å®æ¹åŒãæäŸããããåçãããåå¿äœã¯åºè³ª
ã§ãã€ãŠããããã³ã»ãã¢ã¯ã¿ãŒã§ãã€ãŠãã
ããåãã®äž¡è ã§ãã€ãŠããããããã«ããã®å
çææ®µã«ãããåçã®çµæãšããŠåå¿äœã®ã»ãã«
å°ãªããšãïŒçš®ã®ä»ã®çæç©ãçæãããã該ä»
ã®çæç©ãã詊éšè©Šæäžã«ååšããæŽ»æ§é µçŽ å€æ§
å€ã®å®éçåã¯å®æ§ç枬å®ã«çšããããšãã§ã
ããåå¿äœãåçããææ®µã«ããé µçŽ åå¿é床ã
å®å®åããå®è³ªçãªæéã«ããã€ãŠåå¿éåºŠãæ¬
質äžäžå®ãšãªãã ïŒæ§æã®å ·äœçãªèª¬æïŒ ãã®æçŽ°æžã«ãããŠã¯äžèšã®å®çŸ©ãçšããã ãé µçŽ ãã¯ãåå¿äœãçæç©ã«è»¢æããããã«
æ©èœããè§Šåªéšäœãå°ãªããšãïŒã€æããä»»æã®
èçœè³ªã§ããã ãåå¿äœãã¯ãååŠåå¿ãåããä»»æã®ååŠçš®
ã§ããã ãçæç©ãã¯ãé µçŽ åå¿ãä»ããŠçæããä»»æ
ã®ååŠçååšã§ããã ãåºè³ªãã¯ãããã«å¯ŸããŠé µçŽ ãè§Šåªäœçšãå
ãŒãååŠçååšã§ããã ãã³ã»ãã¢ã¯ã¿ãŒãã¯ãè§ŠåªæŽ»æ§ã®ããã«é µçŽ
ã«å¿ èŠãªéå±ã€ãªã³åã¯ææ©ååããæãååŠç
ååšã§ãããå¿ èŠãªã³ã»ãã¢ã¯ã¿ãŒãé µçŽ ããé€
å»ãããå Žåãé µçŽ ã¯è§Šåªçã«äžæŽ»æ§ãšãªãã ãè£é µçŽ ãã¯ãé µçŽ ã®æ§é ã®ç¹å®ã®éšäœã«çµåã
ãææ©ååã³ã»ãã¢ã¯ã¿ãŒã§ãããè£é µçŽ ã¯ãå š
é µçŽ åå¿ã®éçšã§ç§»åããå®èœåºãç¹å®ã®ååå
ã¯é»åã®äžéæ äœãšããŠæ©èœããã ããªã¬ã³ããã¯ãä»ã®ååãšåå¿ããŠè€åäœã
圢æããä»»æã®ã€ãªã³åã¯ååã§ããã ãäžæ¬¡åå¿ãã¯ãïŒã€ã®åå¿äœã®æ¿åºŠã«çŽæ¥ç
ã«æ¯äŸããé床ã§é²è¡ããé µçŽ åå¿ã§ããã ãäºæ¬¡åå¿ãã¯ãïŒã€ã®åå¿äœã®æ¿åºŠã®ç©ïŒå
ã¯ïŒã€ã®åå¿äœã®æ¿åºŠã®ïŒä¹ïŒã«æ¯äŸããé床ã§
é²è¡ããé µçŽ åå¿ã§ããã ãé¶æ¬¡åå¿ãã¯ãåå¿äœã®æ¿åºŠä»¥å€ã®èŠå ã«ã
ãå€åããé床ã§é²è¡ããé µçŽ åå¿ã§ããããã®
åå¿ã¯éåžžãé µçŽ æ¿åºŠã«æ¯äŸããã ãæŽ»æ§é µçŽ ãã¯ãååšããé µçŽ ã®å šéã®å ãè§Š
åªçã«æ©èœçã§ããããããŠåºè³ªãçæç©ã«è»¢æ
ããããšãã§ããéšåã§ããã ãæŽ»æ§é µçŽ å€æ§å€ãã¯ãé µçŽ ãšçµåããŠé µçŽ æŽ»
æ§ã®åŒ·ããšæ§åŒãå€åããããä»»æã®ååŠçååš
ã§ããã倿§ã«ãããé µçŽ åå¿é床ã®äžæããã
ã¯äœäžãåºè³ªç¹ç°æ§ã®å€åãåã¯é µçŽ æŽ»æ§ã®å€å
ãããã¯é µçŽ æŽ»æ§ã®æ§åŒã®å€åã«ããæ€åºãåŸã
ç¹æ§ã®ä»ã®ä»»æã®å€åãçãããæŽ»æ§é µçŽ å€æ§å€
ã®å€§ããã¯ãå°ååãã巚倧ååãŸã§å€åãåŸ
ããæŽ»æ§é µçŽ å€æ§å€ãšé µçŽ ãšã®çžäºäœçšã¯ãäžé
ååäŒåã®åŒ·ãã«äŸåããŠå¯éçã§ããå Žåãã
ãäžå¯éçã§ããå Žåããããããªãã¡ãäžéå
åäŒåã匱ãå Žåã«ã¯æ¥éã«å¹³è¡¡ã«éããããäž
éååäŒåã匷ãå Žåã«ã¯å¹³è¡¡ã«éããåã¯é ã
平衡ã«éããã ãé µçŽ é»å®³å€ãã¯ãé µçŽ ãšã®çžäºäœçšã«ããé µ
çŽ ã®è§ŠåªæŽ»æ§ãäœäžããããæŽ»æ§é µçŽ å€æ§å€ã§ã
ããé»å®³å€ã®äœçšã®æ§åŒã¯æ®æçãéæ®æçãäž
æ®æçãã¢ãã¹ããªãã¯ãåã¯ãããã®æ§åŒã®çš®
çš®ã®çµåããã§ããã ãå埪ç°ç³»ãã¯ãåå¿çæç©ã«è»¢æãããåºè³ª
ã®éãæå€§ã«ããããã«ç¹ç°çé µçŽ åå¿ã®å®çµã
é§åããããã«ã®ã¿é µçŽ åå¿ã«ã³ã»ãã¢ã¯ã¿ãŒã
äŸçµŠããä»»æã®ååŠåå¿åã¯ååŠåå¿ç³»åã§ã
ãã ãåçææ®µãã¯ãé µçŽ åå¿ã«ããçæãããç
æç©ã®å°ãªããšãïŒçš®ããé µçŽ ã«ããåã³çæç©
ã«è»¢æãããã®ã«é©ããåå¿äœãšããŠåçããã
ãã«å¿ èŠãªåå¿äœãé µçŽ ãè§Šåªãåã³ååŠåå¿å
ã¯ååŠåå¿ç³»åã§ããã ãã®çºæã¯ãæªç¥ã®çµæãæãã詊éšè©Šæäžã®
é µçŽ ã®ååšåã³æ¿åºŠã枬å®ããããã«é µçŽ åå¿ã®
éåºŠãæž¬å®ããåæçæž¬å®æ¹åŒã®æ¹è¯ã«é¢ããã
å žåœ¢çã«ã¯ããã®åæç枬å®ç³»ã¯ãåºè³ªãã³ã»ã
ã¢ã¯ã¿ãŒåã³æŽ»æ§é µçŽ ãå«ãã§æãããã®é µçŽ ã«
ããåºè³ªã®çæç©ãžã®è§Šåªç転æã«ãããååšã
ãæŽ»æ§é µçŽ ã®éãæž¬å®ããããé µçŽ åå¿éåºŠãæ£
ç¢ºã«æž¬å®ããåŸããã®é床ããé µçŽ æ¿åºŠã«å¯ŸããŠ
é床ãããããããæšæºæ²ç·ãšçµã¿åããããã«
ããã詊éšè©Šæäžã«ååšããæŽ»æ§é µçŽ ã®éã®æ£ç¢º
äžã€é«ç²ŸåºŠã®æž¬å®å€ãåŸããããããå Žåã«ã¯ã
掻æ§é µçŽ ã®éã¯ã掻æ§é µçŽ å€æ§å€ã®ååšåã³åœ±é¿
ã«ããå€åãããæ±ããããå¯äžã®æ å ±ã§ããã
ããããªããã蚺æåã¯èšåºã®ããã®åæç枬å®
ç³»ã«ãããŠã¯ãæªç¥éã®æŽ»æ§é µçŽ å€æ§å€ã®ååšäž
ã§è§Šåªçæ©èœãç¶æããæŽ»æ§é µçŽ ã®éã®å€åãã
倿§å€ã®æ¿åºŠã®æž¬å®ã®ããã«æ±ãããããã®å€æ§
å€ã¯ãã°ãã°é µçŽ é»å®³å€ã§ããã ããç¥ãããŠããæŽ»æ§é µçŽ å€æ§å€ã¯ãå¯éçé µ
çŽ é»å®³å€ãã¡ãœãã¬ãã»ãŒãïŒmethotrexateïŒ
ã§ããããã®ãã®ã¯çã®æ²»çã«åºã䜿çšãããã
ãããã®ãã®ã®ååšã®æ£ç¢ºäžã€å®éçãªç£èŠãç¹
ã«å¿ èŠã«ãªã€ããã¡ãœãã¬ãã»ãŒãïŒåã¯ãã®é¡
äœã§ããã¢ãããããªã³ïŒã¯åãããããªã¬ã³ã
ïŒå žåçã«ã¯æåãæäœåã¯çæ³å€ïŒãšæ¥åãã
å Žåã詊éšè©Šæäžã®ä»ã®å¯Ÿå¿ãããªã¬ã³ãã®ç·æ¿
åºŠãæž¬å®ããã®ã«æçšã§ããããããã®æž¬å®æ³ã¯
ãã§ã«èšèŒãããŠããå床詳现ã«åŒçšããå¿ èŠã¯
ãªãããã®ããããã®çºæã®å¥œãŸããå ·äœçæ æ§
ã«ãããŠã¯ãé µçŽ ãžãããããªã¬ãŒãã¬ãã¯ã¿ãŒ
ãŒïŒdihydrofolate reductaseïŒïŒDHFRãšç¥ãïŒ
åã³å¯éçé µçŽ é»å®³å€ã¡ãœãã¬ãã»ãŒããçšãã
ïŒã€ã®ã¢ãã«ãšããŠã®åæç枬å®ç³»ã䜿çšããã
ãã®å ·äœçæ æ§ã«ãããŠã¯ãåŸæ¥ããé·æéã«ã
ããDHFRã®åå¿éåºŠãæ£ç¢ºã«æž¬å®ã§ãããã
ãŠåŸãããå®éšããŒã¿ã«ãããç¹ç°çãªãªã¬ã³ã
ã«çµåãåŸãå€ãã®ç°ãçš®é¡ã®ç©è³ªã®ååšåã³é
ãæ£ç¢ºã«æž¬å®ãããã ãžãããããªã¬ãŒãã¬ãã¯ã¿ãŒãŒïŒDHFRïŒ
ã®åæç枬å®ç³»ã¯ãDHFRã嫿ããæ°Žæº¶æ¶²ã
ãžãããããªã¬ãŒãïŒdihydrofolateïŒïŒFA2ãšç¥
ãïŒãéå åã³ã»ãã¢ã¯ã¿ãŒã§ãããã³ãã³ã¢ã
ãã¢ããã³ãžãã¯ã¬ãªãããã¹ããšãŒã
ïŒnicotinamide adenine dinuclectid phosphate
ïŒNADPHãšç¥ãïŒäžŠã³ã«ãã®æçŽ°æžã«èšèŒãã
çš®ã ã®å¡©åã³ç·©è¡å€ãå«ãã§æããDHFRã¯
NADPHã®ãã³ãã³ã¢ããã¢ããã³ãžãã¯ã¬ãª
ãããã¹ããšãŒãïŒNADPãšç¥ãïŒãžã®é žåãš
åæã«FH2ã®ããã©ãããããªã¬ãŒã
ïŒtetrahydrofolateïŒïŒTH4ãšç¥ãïŒãžã®éå ãè§Š
åªããããã®åå¿ãåå¿åœ¢åŒïŒïŒã«ç€ºãã FH2åã³NADPHã®ããããã¯ãããããä»ã®
é µçŽ çåæçæž¬å®æ³ã«ãããŠäžè¬ã«äœ¿çšããã
ã³ã»ãã¢ã¯ã¿ãŒãšããŠåœæ¥è ã«ããç¥ãããŠã
ããããããªããããã®çºæã®DHFR枬å®ã¢ã
ã«ç³»ã«ãããŠã¯ããããã®åå¿äœã®ããããäžæ¹
ãåºè³ªãšç§°ãã仿¹ãã³ã»ãã¢ã¯ã¿ãŒãšç§°ããã
DHFRåæã¢ãã«ç³»ã«ãããŠãååå¿äœã¯ãä»
æ¹ã®åå¿äœãšã¯ç¬ç«ããŠåçããããšãã§ããã
ããããªãããä»ã®é µçŽ çåæç枬å®ã«ãããŠ
ã¯ããããã®ç©è³ªã¯ãã®é žåååã¯éå åã«ãã
ãŠã第äžã«ãã³ã»ãã¢ã¯ã¿ãŒãšããŠæ©èœãããã®
ãšäºæ³ãããã åå¿åœ¢åŒïŒïŒã«ç€ºãããDHFRåå¿ãé²è¡
ããé床ã¯ã340ããã¡ãŒãã«ïŒnmãšç¥ãïŒã«ã
ããåå¿æº¶æ¶²ã®å åžåã®æžå°ã芳å¯ãïŒãããŠèš
é²ããïŒããšã«ããæž¬å®ããããFH2åã³
NADPHã®äž¡è ã¯ãè©Šéšæ¿åºŠã«ãããŠã340nmã«
ãããŠã»ãšãã©åæ§ã«å ãåžåãããåå¿çæç©
ã§ããFH4åã³NADPã¯ããã®æ³¢é·ã«ãããŠå
ãåžåããªãã DHFR枬å®ã«ãããåå¿é床ã¯ã枬å®ç³»ã«å
åšããè§Šåªçã«æŽ»æ§ãªDHFRã®éã«ããéå®ã
ãããåå¿é床ã¯ã340nmã«ãããå åžåã®çµæ
çæžå°ã«ãã瀺ãããåºè³ªã®è»¢æã®åéåºŠãæž¬å®
ããããšã«ããæ±ºå®ããããåžåã®æžå°é床ãã
枬å®ã«ãããæŽ»æ§DHFRæ¿åºŠã«æ¯äŸããããã®
æ¹æ³ãçšããŠåå¿éåºŠãæ£ç¢ºã«æž¬å®ããããã«
ã¯ãFH2åã³NADPHã®äž¡è ãæåããååšãã
ãããŠDHFRã飜åããã®ã«ååé«ãæ¿åºŠãã
ãªãã¡é µçŽ ã«ååšããè§Šåªéšäœãåå¿ã®ãã¹ãŠã®
æç¹ã«ãããŠåºè³ªã«ããååã«æ¯é ãããŠããã®
ã«ååãªæ¿åºŠã«é£ç¶çã«ç¶æãããããšãå¿ èŠã§
ãããããããªãããåºè³ªåã³ã³ã»ãã¢ã¯ã¿ãŒã®
äž¡è ãšã340nmã«ãããŠå ãåžåããã®ã§ã枬å®
ã«ãããŠãããã®åå¿äœãããã«å€ã䜿çšããã
ã«ã€ããŠã¯å®éäžã®éçããããå ·äœçã«ã¯ãå
å¿äœã340nmã«ãããŠé«ãåžåã瀺ããããããª
ããæž¬å®äžDHFRã®éãšã®é¢é£ã«ãããŠé£œåæ¿
床ãç¶æããªããã°ãªããªããšããïŒã€ã®èŠè«ã®
ããã«ãDHFRãçãæ¿åºŠç¯å²ã§ã®ã¿äœ¿çšãã
ããšãã§ããããŠãã®å Žåã«ã®ã¿æ£ç¢ºãªæž¬å®ãã§
ããã äžèšã®èŠè«ãæºãããªãå Žåã®å¹æã瀺ãã
ããæž¬å®ã«ãã©ãŠã³ïŒBrownïŒçïŒClin.Chem.
26ïŒ355ïŒ1980幎ïŒã®è©Šè¬é åãçšãããè©Šè¬æ
åã®é åæ¿åºŠã第ïŒè¡šã«ç€ºãã 第ïŒè¡š è©Šè¬æå æ¿ 床 FH2 0.085mM NHDPH 0.104mM âã¡ã«ã«ãããšã¿ããŒã« 14.3ÎŒM çé žãããªãŠã 192mM ããªã¹ç·©è¡æ¶² 1.6mM çè¡æž ã¢ã«ããã³ 0.2ïŒ PH 6.5 DHFRã®æ¿åºŠãå€ãããã¹ãŠã®è©Šè¬ã¯äžå®ã«
ããé µçŽ åå¿é床ãçš®ã ã®æç¹ã§æž¬å®ãããå ·äœ
çã«ã¯ãïŒmlã®ãã©ãŠã³ã®è©Šè¬ã30âã«ãŠã€ã³ã
ãŠããŒããããããŠçš®ã ã®æ¿åºŠã®DHFR溶液20ÎŒ
ãå ããããšã«ããé µçŽ åå¿ãéå§ããã
DHFRã®æŽ»æ§åäœãïŒåéã«ïŒãã€ã¯ãã¢ã«ã®
FH2ã®éå ãè§Šåªããé µçŽ ã®éãšããŠå®çŸ©ããã
340nmã«ãããïŒåéåœãã®å åžåã®å€åããïŒ
åéééã§10åéã«ãããæž¬å®ããããšã«ããå
å¿é床ãç£èŠããããã®çµæã第ïŒå³ã®ã°ã©ãã«
瀺ãã 第ïŒå³ã®åæã«ããã°ããã©ãŠã³ã®è©Šè¬é åã«
ãããŠã¯ãDHFRã®æ¿åºŠãéåžžã«äœãå Žåã«ã®
ã¿æéã«é¢ããŠäžå®ã®é µçŽ åå¿é床ãåŸãããã
第ïŒå³ã¯ããã«ãåå¿åœ¢åŒïŒïŒããäž¡åå¿äœã
ããªãã¡åºè³ªïŒFH2ïŒåã³ã³ã»ãã¢ã¯ã¿ãŒ
ïŒNADPHïŒãå¶åŸ¡å åãšãªãäºæ¬¡åå¿ã§ããã
ãšã瀺ããŠãããåŸã€ãŠãåç®äžäžå®ã®åå¿é床
ãåŸãããã«ãããåºè³ªåã³ã³ã»ãã¢ã¯ã¿ãŒã®æ¿
床ãå®è³ªäžé«ãããªããã°ãªãããåã¯PHFRã®
éãäœãæ¿åºŠã«çšéããªããã°ãªããªãã 第ïŒå³ã«ç€ºããããŒã¿ãããã«ããããããäž
çŸ€ã®æ²ç·ãšããŠç¬¬ïŒå³ã«ãããããããåæ²ç·
ã¯ãç°ãæç¹ãç°ãé µçŽ æ¿åºŠã«ãããåå¿é床ã
ããªãŠãããïŒããªãªããã«ïŒmUïŒmlïŒãšããŠ
瀺ãããã®ã§ãããïŒæ¬ã®å®ç·ã¯ã10mUïŒmlæª
æºã®é µçŽ æ¿åºŠã«ãããŠæåã®ïŒåéã«åŸãããé
床ããŒã¿ã倿¿ãããã®ã§ãããDHFRã®èгå¯
ãããåå¿é床ã¯ãé µçŽ æ¿åºŠã®äžæã«åŸã€ãŠå®ç·
ããåçã«ããã¯ãªããããšãæããã§ãããã
ãã«ãåå¿é床ãæåã®ïŒåéã«æž¬å®ããå Žåã§
ãããDHFRæ¿åºŠãé«ããªãã«åŸã€ãŠè¥å¹²éçŽ
ç·çã«ãªãããããŠãããã®DHFRæ¿åºŠã«ãã
ãŠããçŽç·æ§ããã®åå·®ã¯ãåå¿æéãé·ããªã
ã«åŸã€ãŠã ãã ã倧ãããªãããšãæããã§ã
ãã éççãªããŒã¿ãã°ã©ãã«ããããããããã«
çŽç·ãé©çšããããšã«ãã€ãŠèŠããäžåççãªçŽ
ç·ãåŸãããããããã©ãŠã³ã®è©Šè¬é åãçšãã
DHFR枬å®ã«ãããåå¿é床ã®éçŽç·æ§ã¯ãäž
泚æãªèгå¯è ã«ãšã€ãŠã¯æããã§ã¯ãªããåå¿ã®
åæéåºŠãæž¬å®ããæ¡ä»¶äžã§ã®çŽç·æ§ããã®å€§ã
ãªåå·®ã¯ãéåžžãææ³ã®å·®ãåºè³ªã®æ¶è²»åã³çæ
ç©ã«ãããã€ãŒãããã¯é»å®³ã®ããã§ãããšã
ããåŸã€ãŠç¡èŠãããŠããŸããããããªããã第
ïŒå³åã³ç¬¬ïŒå³ã«ç€ºãããããŒã¿ãæ³šææ·±ã芳å¯
ããã°ããã©ãŠã³ã®è©Šè¬ã«ããæž¬å®ã¯ãäœãåºè³ª
æ¿åºŠã«ãããŠå®æœããå Žåã«ã®ã¿åç®äžçŽç·çã§
ããããšãæãããšãªããæã倧ããªèª€å·®åã³å
å·®ã¯ã掻æ§é µçŽ å€æ§å€ãåã¯æŽ»æ§é µçŽ å€æ§å€ã®ãª
ã¬ã³ãæ¥åç©ãšçµåãåŸãç©è³ªã®ååšã枬å®ãã
ããã®é µçŽ æž¬å®ã«ãããŠé«æ¿åºŠã®DHFRã䜿çš
ãããããšã«äŒŽã€ãŠçããã ãã©ãŠã³ã®è©Šè¬ãçšããæž¬å®ç³»ã«ãããæ¬ ç¹ã
èªèããäžã§ãé µçŽ æž¬å®ã«ãããŠã芳å¯ãããå
å¿é床ã®å®è³ªäžæ¹è¯ãããçŽç·æ§ãäŸãããã®çº
æã®ïŒã€ã®æ æ§ãåå¿åœ¢åŒïŒïŒã«ç€ºãã ãã®åå¿ã«ãããŠã¯ãDHFR枬å®ç³»ã«é µçŽ ã°
ã«ã³ãŒã¹âïŒâãã¹ããšãŒãããããã²ããŒãŒ
ïŒG6PDHïŒãå«ããæåã®äœ¿çšæ¿åºŠã第ïŒè¡šã«
瀺ãã 第ïŒè¡š è©Šè¬æå æ¿ 床 FH2 0.12mM NADPH 0.065mM âïŒâ 3.3mM G6PDH 1UïŒml ããªã¹ç·©è¡æ¶² 114mM MOPSOç·©è¡æ¶² 80mM ãžããªãšãªã¹ãªããŒã« 6mM PH 7.0 ãã®è¿œå ã®é µçŽ ã®ããã®åºè³ªã¯ã°ã«ã³ãŒã¹âïŒ
âãã¹ããšãŒãïŒG6PïŒã§ããããã®åºè³ªã¯ãã«
ã¿âïŒâãã¹ãã°ã«ã³ãã©ã¯ãã³ïŒÎŽâ6PGïŒã«
転æããããG6PDHåã³ïŒ§âïŒâã¯äžç·ã«ãª
ã€ãŠãDHFRé µçŽ åå¿ã«ããå ç«ã€ãŠçæãã
NADPããã®NADPHã®åçææ®µãæ§é ããã
ãã®NADPHåçææ®µãããã«äžè¬çã«ã³ã»ã
ã¢ã¯ã¿ãŒåçææ®µãšç§°ããã DHFR枬å®ç³»ã«å¯Ÿããã³ã»ãã¢ã¯ã¿ãŒåçæ
段ã®å¹æãã°ã©ãã«ããããããŠç¬¬ïŒå³åã³ç¬¬ïŒ
å³ã«ç€ºãããã®ããŒã¿ã¯æ¬¡ã®ããã«ããŠåŸãã
ããïŒmlã®è©Šè¬ã37âã«ãŠã€ã³ããŠããŒãããã
ããŠ0.0ã40mUïŒmlã®çš®ã ã®æ¿åºŠã«çšéãã
DHFR溶液20ÎŒãå ããããšã«ããé µçŽ åå¿ã
éå§ããã340nmã«ãããå åžåã®ïŒåéåœãã
ã®å€åãïŒåéééã§10åéã«ãããæž¬å®ããã
ãšã«ããåå¿é床ãç£èŠããã 第ïŒå³ã®ããŒã¿ãããNADPHåçææ®µã¯ã
é«ãDHFRæ¿åºŠã«ãããŠã10åéã®è©Šéšæéã«
ããã€ãŠå®è³ªäžäžå®ã®é µçŽ åå¿é床ãäŸããããš
ãæããã§ããã第ïŒå³ã®ããŒã¿ã第ïŒå³ã«åã
ããããããŠããããã®ç¬¬ïŒå³ã«ããã40mUïŒ
mlã®DHFRæ¿åºŠã«ãããŠãããã³ã»ãã¢ã¯ã¿ãŒ
åçææ®µãçŽç·æ§ãé¡èã«æ¹è¯ããããšã瀺ãã
ããå®ç·ã§ç€ºãããçŽç·ã¯ãåå¿ã®ç¬¬ïŒã®ïŒåé
ã®éã«æž¬å®ãããé床ããŒã¿ã倿¿ããŠåŸããã®
ã§ãããåå¿æéäžã®æåã®ïŒåéã®åŸã«ãããŠ
ã®ã¿DHFRåå¿é床ãæåã®åå¿é床ãããã
å§ããã芳å¯ããããããã®åå·®ã®æ·±å»ããã第
ïŒå³ã«ç€ºããããã©ãŠã³ã®è©Šè¬ã®å Žåã®ããã«æ¯
ã¹ãŠçžå¯Ÿçã«å°ããããšã¯ç¢ºå®ã§ãããDHFR
枬å®ç³»ã«ã³ã»ãã¢ã¯ã¿ãŒåçææ®µãå«ããããšã«
ããå šäœç广ã¯ãDHFRäºæ¬¡åå¿ãã
NADPHããã¯ãé žçŽ åå¿é床ãå¶åŸ¡ãåã¯ã
ãã«åœ±é¿ãäžããèŠçŽ ã§ã¯ãªãäžæ¬¡åå¿ã«å€ãã
ç¹ã«ããã DHFRåå¿ç³»ã«ã¡ãœãã¬ãã»ãŒãã®ããšã掻
æ§é µçŽ å€æ§å€ãå«ããå Žåã«ã¯è¿œå ã®è€éããç
ããã第ïŒã«ãã¡ãœãã¬ãã»ãŒãã«ããDHFR
ã®é»å®³ã¯å³æã«çããã®ã§ãªããDHFRåå¿é
床ã®èšé²ãåŸãé»å®³ãçããã®ã«å ç«ã€ãŠèгå¯ã
åŸãã©ã°æéãçããã第ïŒã«ãé»å®³å€ã«ããã©
ã°æéãèªå°ããããããDHFRåå¿é床ãå»¶
é·ãããæéã«ããã€ãŠããããåååŠçæ¡ä»¶äž
ã§æž¬å®ããå¿ èŠãããããããã®æž¬å®ææ®µã¯ãå
èšã®DHFRåå¿ã®åææ®µéã«ããããããšéåžž
ã«ç°ãªãããã®ãããªå€åããæ æ³ã«ãããå šäœ
çãªå¹æã¯ãDHFRæ¿åºŠãäžå®ã«ããé»å®³å€ã®
æ¿åºŠãã ãã ãé«ãããå Žåã®DHFRåå¿é床
ã®çŽç·æ§ãæ¯èŒããããšã«ãã瀺ãããããã®æ¯
èŒãã第ïŒè¡šã«ç€ºãè©Šè¬æåãçšããåå¿åœ¢åŒ
ïŒïŒã«ç€ºããã³ã»ãã¢ã¯ã¿ãŒåçææ®µã䜿çšã
ãŠãåã¯äœ¿çšããªãã§è¡ã€ãããã¹ãŠã®å Žåã«ã
ããŠDHFRã®éãåºå®ãããããŠG6PDHã¯èšèŒ
ããéã ã䜿çšãåã¯å šã䜿çšããªãã€ããæ¯èŒ
ã®çµæã第ïŒïŒïŒåã³ïŒå³ã«ç€ºãã 第ïŒè¡š è©Šè¬æå æ¿ 床 FH2 0.12mM NADPH 0.065mM âïŒâ 3.3mM G6PDH 1UïŒmlåã¯ç¡ã ããªã¹ç·©è¡æ¶² 114mM MOPSOç·©è¡æ¶² 80mM ãžããªãšãªã¹ãªããŒã« 6mM PH 7.0 MTXâDPH ïŒã10-6ïŒ ç¬¬ïŒå³ã¯ãDHFRåå¿ã®èгå¯ãããåå¿é床
ããçš®ã ã®æ¿åºŠã®æŽ»æ§é µçŽ é»å®³å€ã®ååšäžã§ã
ã³ã»ãã¢ã¯ã¿ãŒåçææ®µã䌎ã€ãŠåã¯äŒŽããªã
ã§ãé·æéã«ããã€ãŠæ¯èŒãããã®ã§ããã第ïŒ
衚ã«ç€ºãè©Šè¬æåïŒmlã37âã«ãŠã€ã³ããŠããŒã
ãããããŠ1UïŒmlã®DHFR溶液20ÎŒãå ããã
ãšã«ããåå¿ãéå§ããã340nmã«ãããå åžå
ã®ïŒåéåœãã®å€åãïŒåéééã§10åéã«ãã
ãæž¬å®ããããšã«ããåå¿é床ãç£èŠãããããŒ
ã¿ãåäžæ¡ä»¶äžã§åŸããäœããäžçµã®æž¬å®ã«ãã
ãŠã¯NADPHåçææ®µãçšãïŒå®ç·ã®æ²ç·ã§ç€º
ãïŒãä»ã®äžçµã®æž¬å®ã«ãããŠã¯ïŒ§âïŒâPDHæ
åãçšããªãã€ãïŒç Žç·ã®æ²ç·ã§ç€ºãïŒããã¹ãŠ
ã®æž¬å®æ··åç©ã«ã¯äžå®éã®DHFRãšçš®ã ç°ãªã
æ¿åºŠã®DHFRé»å®³å€ã嫿ããããããã®ç ç©¶
ã«ãããŠã¯ãé»å®³å€ãšããŠã¡ãœãã¬ãã»ãŒãã®ãª
ã¬ã³ãæ¥åäœãããªãã¡æçæ£å€ã§ãããžããšã
ã«ããã³ãã€ã³ã®å ç«æž¬å®ã«äœ¿çšãããγâïŒïŒïŒ
ïŒâãžããšãã«ããã³ãã€ã³âïŒâã¢ã»ãããã©
ãžãïŒâã¡ãœãã¬ãã»ãŒãïŒMTXâDPHïŒã䜿
çšãããMTXâDPHã¯ã(a)ïŒã(b)ïŒÃ10-8ïŒã
(c)ïŒÃ10-8ïŒã(d)ïŒÃ10-7ïŒã(e)ïŒÃ10-7ïŒåã³
(f)ïŒÃ10-6ïŒã®è©Šéšæ¿åºŠã§æ·»å ããã äžè¬ã«ã第ïŒå³ã第ïŒå³ãããé»å®³å€ã®æ¿åºŠã
å¢å ããã«åŸã€ãŠæž¬å®ãåŸãDHFR掻æ§ãäœäž
ããããšãããããããããªããã第ïŒå³ã®ããŒ
ã¿ã¯ãã³ã»ãã¢ã¯ã¿ãŒåçææ®µãçšããªã
DHFRæž¬å®æ³ã«ãããŠã¯ãé»å®³å€ã§ããMTXâ
DPHã®åè©Šéšæ¿åºŠã«ã€ããŠåå¿é床ãç°ãªããã
ããããã®åå¿é床ã¯é£ç¶çã«äœäžããããšã瀺
ããŠããã åŸã€ãŠããã®é»å®³å€ãããæªç¥ã®æ¿åºŠã§å«æã
ãïŒã€ã®è©Šéšè©Šæãããåºç¯å²ã«ç°ãªãDHFR
åå¿é床ãå®éšçã«æ±ãããããã®ããããã®å
å¿é床ã«ããïŒã€ã®è©Šéšè©Šæã«ã€ããŠç°ãªã
MTXâDPHæ¿åºŠã瀺ãããããšãæããã§ã
ããããã«å¯ŸããŠãDHFR枬å®ã«ã³ã»ãã¢ã¯ã¿
ãŒåçææ®µãçµåãããå Žåã«ã®ã¿èгå¯ãããå
å¿é床ãäžå®ãšãªãããããŠïŒåéã«ãããåŸé
ãé¶ã«ãªãã DHFR掻æ§ã¯é»å®³å€ã®æ¿åºŠã«åæ¯äŸãããšäº
æ³ããããããé»å®³å€ã®æ¿åºŠã®éæ°ã«å¯ŸããŠ
DHFRåå¿é床ãããããããã°ã©ãã¯å®è³ªäž
çŽç·ã«ãªãããšãäºæ³ãããã第ïŒå³åã³ç¬¬ïŒå³
ã«ããªã¬ã³ãã«æ¥åããé»å®³å€ã®ååšäžã§ã
NADPHã®ããã®ã³ã»ãã¢ã¯ã¿ãŒåçææ®µãçš
ãåã¯çšããªãå Žåã«ãããDHFR枬å®ã®çŽç·
æ§ã«å¯Ÿããåå¿æéã®åœ±é¿ã瀺ãã第ïŒå³ã«ç€ºã
ããŒã¿ã¯ç¬¬ïŒå³ã®ç Žç·ãšåãã§ããããé床ã
MTXâDPHæ¿åºŠã®éæ°ã®é¢æ°ãšããŠããããã
ãŠãããåæ²ç·ã¯ãå³ã«ç€ºãããæç¹ã§éåºŠãæž¬
å®ããå Žåã®çŽç·æ§ã«å¯Ÿå¿ããæçã«ããããïŒ
åéééã§ç€ºããŠãããçšããMTXâDPHã®æ¿
床ã¯ããããïŒÃ10-8ïŒãïŒÃ10-7ïŒãïŒÃ10-7
ïŒãïŒÃ10-6ïŒãåã³ïŒÃ10-6ïŒã§ããã 第ïŒå³ãããã³ã»ãã¢ã¯ã¿ãŒåçææ®µãçšããª
ãDHFR枬å®ã«ãããŠã¯ãæéã«åŸã€ãŠå€§ãã
å€åããäžçŸ€ã®é床å¿çæ²ç·ãåŸãããããšãæ
ããã§ãããããã«å¯ŸããŠãDHFR枬å®ã«ã³ã»
ãã¢ã¯ã¿ãŒåçææ®µãçšããå Žåã第ïŒå³ã«ç€ºã
ããã«ãDHFRé»å®³ã®çšåºŠã¯åççã«äžå®ã«ç¶
æããããããŠé»å®³å€ã®çšããããæ¿åºŠç¯å²ã«ã
ããŠåçŸæ§ãããã第ïŒå³ã®ããŒã¿ã¯ç¬¬ïŒå³ã®å®
ç·ã®æ²ç·ããåã€ããã®ã§ãããäœããé床ã
MTXâDPHæ¿åºŠã®éæ°ã®é¢æ°ãšããŠããããã
ããã®ã§ããã DHFR枬å®ç³»ã«ãããŠã³ã»ãã¢ã¯ã¿ãŒåçæ
段ã«ãã€ãŠäŸãããæãåçãªæ¹è¯ã¯ïŒã€ã®é
åãããªãã¡é»å®³å€ã®æ¿åºŠãæ¯èŒçé«ãåå¿é床
ãäœãå Žåãåã³é·æéã«ããã€ãŠé»å®³å€ã®æ¿åºŠ
ãéåžžã«äœãå Žåã§ãããæŽ»æ§é µçŽ å€æ§å€ã®ååš
äžã§ã®é床å¿çæ²ç·ã®çŽç·æ§ãã³ã»ãã¢ã¯ã¿ãŒå
çç³»ã«ããåçã«æ¹è¯ãããçç±ã¯ãã³ã»ãã¢ã¯
ã¿ãŒåçç³»ã«ãããäºååçãªäºæ¬¡åå¿ãäžåå
çãªäžæ¬¡åå¿ã«å¹æçã«å€åããããšã§ãããã
ã®ããšã¯NADPHã®æ¿åºŠããNADPHã«ã€ããŠ
ã®DHFRã®Kmå€ããé«ãäžå®ã®å€ã«ç¶æããã
ããšã«ããéæãããã ãã®çºæã®å¥œãŸããæ æ§ã«ãããŠã¯ãããã©ãŸ
ãªãŠã è²çŽ ïŒâïŒïŒïŒïŒâãžã¡ãã«ãã¢ãŸãŒã«â
ïŒâã€ã«ïŒâïŒïŒïŒâãžããšãã«â2Hâããã©ãŸ
ãªãŠã ããããïŒMTTïŒãDHFRã«ããçæã
ãFH2ã®FH2ãžã®åçãšéé µçŽ çã«å ±åœ¹ãã
DHFR枬å®ç³»ã®ããã®åºè³ªåçææ®µãçšããã
ãã®åºè³ªåçææ®µãåå¿åœ¢åŒïŒïŒã«èšèŒããã åºè³ªåçææ®µã¯ããã©ãŸãªãŠã è²çŽ MTTãã
æãããã®ãã®ã¯FH4ãFH2ã«è»¢æããããã«
ã³ã»ãã¢ã¯ã¿ãŒåçææ®µåã³åèšã®DHFR枬å®
ã«å ãããããåååŠçã«ã¯ãDHFRã«ãã
FH4ãçæããã«åŸãMTTãFH4ãšçµåãã
FH2ãåçãããšåæã«å¯çç©ãšããŠã¬ãããã«
ãã¶ã³è²çŽ ãçæãããã¬ãããã«ãã¶ã³è²çŽ ã¯
340nmã§ã¯ãªã568nmã«ãããŠã®ã¿å ãåžåã
ããåŸã€ãŠãFH2ã®åçã«äŒŽã€ãŠãFH4ã®FH2ãž
ã®ã¢ã«âã¢ã«è»¢æã瀺ã568nmã«ãããå åžåã®
å¢å ã芳å¯ããããDHFR枬å®ç³»ã«ãããŠãã®
åºè³ªåçææ®µãã³ã»ãã¢ã¯ã¿ãŒåçææ®µãšçµåã
ããŠäœ¿çšããå Žåãåçåå¿ã®ãã®çµåããã«ã
ããæåäºæ¬¡åå¿ã§ãã€ãåå¿ãé¶æ¬¡åå¿ã«å€ã
ããããã«äŒŽã€ãŠãDHFR枬å®ã«ãããé µçŽ å
å¿é床ã®çŽç·æ§ãããã«å®è³ªçã«å¢å ããã é床ã®çŽç·æ§ã®è¿œå ã®å¢å ã第ïŒå³ã®ã°ã©ãã«
瀺ãããã®ã°ã©ãã«ãããŠã¯ãé µçŽ é»å®³å€MTX
âDPHã®ååšäžã«ãããåºè³ªåçææ®µã®ã¿ã䜿
çšããDHFR枬å®ãšåºè³ªåçææ®µãšã³ã»ãã¢ã¯
ã¿ãŒåçææ®µãçµåãããŠäœ¿çšããDHFR枬å®
ãšãæ¯èŒãããŠããã åå¿æåã第ïŒè¡šã«ç€ºãã 第ïŒè¡š åå¿æå æ¿ 床 FH2 0.4mM NADPH 0.065mM MTT 0.12mM âïŒâ âŠ3.3mM G6PDHã 1UïŒmlïœåã¯ç¡ã ããªã¹ 114mM MOPSO 80mM DTE ïŒ PH 7.0 MTXâDPH ïŒã10-6ïŒ äžèšã®é»å®³è©Šè¬ïŒmlã37âã«ãããŠã€ã³ããŠã
ãŒããããããŠãDHFRã®ã¹ããã¯æº¶æ¶²ïŒ1UïŒ
mlïŒ20ÎŒãå ããããšã«ããé»å®³åå¿ãéå§ã
ããåå¿é床ã568nmã«ãããå åžåã®å€åãïŒ
åéééã§10åéã«ãããç£èŠããã ãã®æž¬å®ã®çµæãäžé£ã®æ²ç·ãšããŠç¬¬ïŒå³ã«ã°
ã©ããšããŠç€ºããå®ç·ã®æ²ç·ã¯NADPHåçæ
段åã³FH2åçææ®µã®äž¡æ¹ã®å¹æãéãªã€ãå Žå
ã瀺ããç Žç·ã®æ²ç·ã¯G6PDHãçšããªãFH2å
çææ®µã®ã¿ã®å¹æã瀺ããé»å®³å€MTXâDPHã®
è©Šéšæ¿åºŠã¯æ¬¡ã®éããšãããããªãã¡(a)ïŒã(b)ïŒ
Ã10-8ïŒã(c)ïŒÃ10-8ïŒã(d)ïŒÃ10-7ïŒã(e)ïŒÃ
10-7ïŒïŒåã³(f)ïŒÃ10-6ïŒã§ããã第ïŒå³ããã
åºè³ªåçææ®µåã³ã³ã»ãã¢ã¯ã¿ãŒåæææ®µãçµå
ãããŠäœ¿çšããDHFRåæç枬å®ã«ãããŠãé»
害å€ã®è©Šéšããã»ãšãã©å šæ¿åºŠç¯å²ã«ããããã
ããŠ10åéãè¶ ããå šè©Šéšæéã«ãããã
DHFRåå¿é床ã®çŽç·æ§ãåŸãããããšã容æ
ã«çè§£ã§ãããæããã«ãçŽç·æ§ã®è¿œå ã®å¢å
ã¯ãã³ã»ãã¢ã¯ã¿ãŒåçææ®µã䌎ãå Žåãš
DHFR枬å®ç³»ã®ã¿ãæ¯èŒãã第ïŒå³ã«ãããå Ž
åãšåæ§ã«åçã§ããã åå¿æ¹åŒïŒïŒã®åºè³ªåçææ®µã®å¹æãããã«
æç¢ºã«ç€ºãããã«ã第ïŒå³ã®ããŒã¿ã第ïŒå³åã³
第ïŒïŒå³ã«ãããŠã°ã©ããšããŠåããããããã 第ïŒå³ã¯ãMTXâDPHã®ååšäžã§FH2ã®ãã
ã®åºè³ªåçææ®µã®ã¿ãçšããDHFR枬å®ã®çŽç·
æ§ã«åãŒãæéã®åœ±é¿ã瀺ãããã®ããŒã¿ã¯ç¬¬ïŒ
å³ã«ãããç Žç·ã®æ²ç·ã®ããŒã¿ãšåãã§ãããäœ
ããé床ãé»å®³å€ã®æ¿åºŠã®éæ°ã®é¢æ°ãšããŠãã
ããããŠããã第ïŒå³äžã®åæ²ç·ã¯ãã°ã©ãã«è¡š
瀺ããæç¹ã§éåºŠãæž¬å®ããå Žåã«åŸãããçŽç·
æ§ã«å¯Ÿå¿ãããå®éã«äœ¿çšããMTXâDPHã®æ¿
床ã¯ïŒÃ10-8ïŒãïŒÃ10-7ïŒãïŒÃ10-7ïŒãïŒÃ
10-6ïŒãåã³ïŒÃ10-6ïŒã§ããã 第ïŒïŒå³ã¯ãFH2åã³NADPHã®ããã®äž¡åç
ææ®µãååšããå Žåã«åŸãããDHFRâé»å®³å€
枬å®ã®ããã«æ¹è¯ãããçŽç·æ§ã瀺ããããŒã¿ã¯
第ïŒå³ã®å®ç·ã®æ²ç·ãšåãã§ãããäœããé床ã
MTXâDPHæ¿åºŠã®éæ°ã®é¢æ°ãšããŠããããã
ãŠãããæž¬å®æéåã³é»å®³å€ã®æ¿åºŠã¯ç¬¬ïŒå³ã®å Ž
åã®ãããšåãã§ããã 第ïŒå³ãšç¬¬ïŒïŒå³ã®æ¯èŒããæãããªéããåº
質åçææ®µåã³ã³ã»ãã¢ã¯ã¿ãŒåçææ®µã®äž¡æ¹ã
çšããå Žåãé»å®³ãããDHFR枬å®ç³»ã«ããã
çŽç·æ§ã®ããã¯éåžžã«å°ãããªããå®éšç枬å®ã®
ç²ŸåºŠãæ¹è¯ãããã第ïŒå³ã«ãããããŒã¿ã«ãã
瀺ãããçŽç·æ§ããã®åå·®ã¯ãåºè³ªã§ããFH2ã®
é£œåæ¿åºŠã§ã®ååšäžã§ã³ã»ãã¢ã¯ã¿ãŒã§ãã
NADPHãæ¶è²»ãããããšã«èµ·å ãããšä¿¡ãã
ããããã®ããŒã¿ã¯ãåæ§ã®è©Šéšæ¡ä»¶ã®äžã§ã
ã³ã»ãã¢ã¯ã¿ãŒã§ããNADPHã®é£œåæ¿åºŠã§ã®
ååšäžã§ã®åºè³ªã§ããFH2ã®æ¶è²»ã®å¹æã瀺ã第
ïŒå³ã®ããŒã¿ãšé©åã«å¯Ÿæ¯ããããé床ã®çŽç·æ§
ããã®åå·®ã®çšåºŠãåäžã§ãªãããšãæããã§ã
ãããã®ããã«å¹æãç°ãã®ã¯ãé µçŽ ã§ãã
DHFRãšåºè³ªã§ããFH2ãšã®éã®Kmã«ãã€ãŠæž¬
å®ãããçµåèŠªåæ§ãšãDHFRãšã³ã»ãã¢ã¯ã¿
ãŒã§ããNADPHãšã®éã®çµåèŠªåæ§ãšã®çžç°
ã«ãããã®ãšä¿¡ãããããåçµåèŠªåæ§ã«ããã
å·®ç°ã䞊ã³ã«ç¬¬ïŒå³åã³ç¬¬ïŒå³ã®ããŒã¿ã¯ã枬å®
ç³»ã«ãããŠãé µçŽ DHFRã¯NADPHãšããã
FH2ãšãã匷ãçµåããããšãæããã«ç€ºããŠã
ãããã®èгå¯ã¯ãç ç©¶è ãåå¿é床ã®çŽç·æ§ãæ¹
è¯ããããã«ã³ã»ãã¢ã¯ã¿ãŒåçææ®µåã¯åºè³ªå
çææ®µã®ïŒæ¹ã®ã¿ã®äœ¿çšãéžæããªããã°ãªããª
ãç¶æ³ã«ãããŠç¹ã«æçšã«ãªãã ãã®çºæã®å¥œãŸããæ æ§ããDHFRãçšãã
åæç枬å®ç³»ã«é¢ããŠèª¬æããããã³ã»ãã¢ã¯ã¿
ãŒåã³ïŒåã¯åºè³ªãåçããããã®ææ®µãçšãã
ããšã«ãããäžè¬çã«ããããé µçŽ æž¬å®ç³»ã«ãã
ãŠåå¿é床ã®çŽç·æ§ãå®è³ªçã«æ¹è¯ããããšãã§
ãããããã®ãããªåçææ®µãçšããããšã«ã
ããçšããé µçŽ ç³»ã®ãããã«ããããããåžžã«ã
äžå±€åäžäžã€äžè²«ããé µçŽ è§Šåªã®åå¿é床ãåŸã
ããããåçã«æé©ãªãã®ã¯åžžã«å¿ é æåãšèã
ãããæ¯èŒçå°æ°ã®ã³ã»ãã¢ã¯ã¿ãŒã§ãããã³ã»
ãã¢ã¯ã¿åçææ®µã奜ãŸããåçææ®µã§ãããé
床ã®çŽç·æ§ã®åäžã䌎ã€ãŠä»ã®å€ãã®é µçŽ ç³»ã®äž
éšãšããŠåçããããšãã§ããã³ã»ãã¢ã¯ã¿ãŒã
第ïŒè¡šã«åæãããäœããããã«éå®ããããã®
ã§ã¯ãªãã ã衚ã ã衚ã åã¯ãã«ããã
åº
åæ§ã«ãä»ã®åæçé µçŽ æž¬å®ç³»ã«ãããŠãåç
ææ®µã䜿çšããããšã«ããäºæ¬¡åå¿ç³»ãäžæ¬¡åå¿
ç³»ã«å€ãããããã«å¯Ÿå¿ããŠæž¬å®ãåŸãé床ã®çŽ
ç·æ§åã³åçŸæ§ãé«ãããããDHFR枬å®ä»¥å€
ã®é µçŽ ç³»ã«ãããåå¿äœã®åçã®ããã®ç¹ç°çå
çææ®µããåãªãäŸãšããŠç¬¬ïŒè¡šã«ç€ºãã ã衚ã ãã³
ã¯ã¬ã¢ãã³ãããŒãŒ
第ïŒå³ã¯é
µçŽ ãžãããããªã¬ãŒãã¬ãã¯ã¿ãŒãŒ
ã®æ¿åºŠãå€ããå Žåã®é µçŽ åå¿é床ã®äœäžãæé
ã®é¢æ°ãšããŠç€ºããã°ã©ãã§ããã第ïŒå³ã¯ã第
ïŒå³ã«ããããããé µçŽ çæž¬å®ã®çŽç·æ§ã«äžãã
æéã®åœ±é¿ã瀺ãã°ã©ãã§ããã第ïŒå³ã¯ã枬å®
ã«ã³ã»ãã¢ã¯ã¿ãŒåçææ®µãå°å ¥ããå Žåã®ãžã
ããããªã¬ãŒãã¬ãã¯ã¿ãŒãŒã®é µçŽ åå¿é床ãæ
éã®é¢æ°ãšããŠç€ºãã°ã©ãã§ããã第ïŒå³ã¯ããž
ãããããªã¬ãŒãã¬ãã¯ã¿ãŒãŒæž¬å®ã«ãããæ¹è¯
ãããçŽç·æ§ã第ïŒå³ã®ããŒã¿ãçšããŠç€ºãã°ã©
ãã§ããã第ïŒå³ã¯ãã³ã»ãã¢ã¯ã¿ãŒåçææ®µã®
ååšäžåã¯éååšäžã§é»å®³å€ã®æ¿åºŠãå€ããå Žå
ã®é µçŽ åå¿é床ãæéã®é¢æ°ãšããŠæ¯èŒããã°ã©
ãã§ããã第ïŒå³ã¯ããžãããããªã¬ãŒãã¬ãã¯
ã¿ãŒãŒãçšããé»å®³å€ã®æž¬å®ã®çŽç·æ§ã第ïŒå³ã®
ããŒã¿ãçšããŠç€ºãã°ã©ãã§ããã第ïŒå³ã¯ã
ã³ã»ãã¢ã¯ã¿ãŒåçææ®µãååšããå Žåã®ãžãã
ãããªã¬ãŒãã¬ãã¯ã¿ãŒãŒã«ããé»å®³å€ã®æž¬å®ã«
ãããçŽç·æ§ã®æ¹è¯ã第ïŒå³ã®ããŒã¿ãçšããŠç€º
ãã°ã©ãã§ããã第ïŒå³ã¯ããžãããããªã¬ãŒã
ã¬ãã¯ã¿ãŒãŒæž¬å®ã«ãããŠãã³ã»ãã¢ã¯ã¿ãŒåç
ææ®µãåºè³ªåçææ®µãšçµåãããå Žåã®å¹æã瀺
ãã°ã©ãã§ããã第ïŒå³ã¯ãåºè³ªåçææ®µã®ã¿ã
䜿çšããå Žåã®ãžãããããªã¬ãŒãã¬ãã¯ã¿ãŒãŒ
枬å®ã®çŽç·æ§ã«åãŒãæéã®åœ±é¿ã第ïŒå³ã®ããŒ
ã¿ãçšããŠç€ºãã°ã©ãã§ããããããŠã第ïŒïŒå³
ã¯ãã³ã»ãã¢ã¯ã¿ãŒåçææ®µåã³åºè³ªåçææ®µã
çšããé µçŽ æž¬å®ã®çŽç·æ§ã«åãŒãæéã®åœ±é¿ã第
ïŒå³ã®ããŒã¿ãçšããŠç€ºãã°ã©ãã§ããã
ã®æ¿åºŠãå€ããå Žåã®é µçŽ åå¿é床ã®äœäžãæé
ã®é¢æ°ãšããŠç€ºããã°ã©ãã§ããã第ïŒå³ã¯ã第
ïŒå³ã«ããããããé µçŽ çæž¬å®ã®çŽç·æ§ã«äžãã
æéã®åœ±é¿ã瀺ãã°ã©ãã§ããã第ïŒå³ã¯ã枬å®
ã«ã³ã»ãã¢ã¯ã¿ãŒåçææ®µãå°å ¥ããå Žåã®ãžã
ããããªã¬ãŒãã¬ãã¯ã¿ãŒãŒã®é µçŽ åå¿é床ãæ
éã®é¢æ°ãšããŠç€ºãã°ã©ãã§ããã第ïŒå³ã¯ããž
ãããããªã¬ãŒãã¬ãã¯ã¿ãŒãŒæž¬å®ã«ãããæ¹è¯
ãããçŽç·æ§ã第ïŒå³ã®ããŒã¿ãçšããŠç€ºãã°ã©
ãã§ããã第ïŒå³ã¯ãã³ã»ãã¢ã¯ã¿ãŒåçææ®µã®
ååšäžåã¯éååšäžã§é»å®³å€ã®æ¿åºŠãå€ããå Žå
ã®é µçŽ åå¿é床ãæéã®é¢æ°ãšããŠæ¯èŒããã°ã©
ãã§ããã第ïŒå³ã¯ããžãããããªã¬ãŒãã¬ãã¯
ã¿ãŒãŒãçšããé»å®³å€ã®æž¬å®ã®çŽç·æ§ã第ïŒå³ã®
ããŒã¿ãçšããŠç€ºãã°ã©ãã§ããã第ïŒå³ã¯ã
ã³ã»ãã¢ã¯ã¿ãŒåçææ®µãååšããå Žåã®ãžãã
ãããªã¬ãŒãã¬ãã¯ã¿ãŒãŒã«ããé»å®³å€ã®æž¬å®ã«
ãããçŽç·æ§ã®æ¹è¯ã第ïŒå³ã®ããŒã¿ãçšããŠç€º
ãã°ã©ãã§ããã第ïŒå³ã¯ããžãããããªã¬ãŒã
ã¬ãã¯ã¿ãŒãŒæž¬å®ã«ãããŠãã³ã»ãã¢ã¯ã¿ãŒåç
ææ®µãåºè³ªåçææ®µãšçµåãããå Žåã®å¹æã瀺
ãã°ã©ãã§ããã第ïŒå³ã¯ãåºè³ªåçææ®µã®ã¿ã
䜿çšããå Žåã®ãžãããããªã¬ãŒãã¬ãã¯ã¿ãŒãŒ
枬å®ã®çŽç·æ§ã«åãŒãæéã®åœ±é¿ã第ïŒå³ã®ããŒ
ã¿ãçšããŠç€ºãã°ã©ãã§ããããããŠã第ïŒïŒå³
ã¯ãã³ã»ãã¢ã¯ã¿ãŒåçææ®µåã³åºè³ªåçææ®µã
çšããé µçŽ æž¬å®ã®çŽç·æ§ã«åãŒãæéã®åœ±é¿ã第
ïŒå³ã®ããŒã¿ãçšããŠç€ºãã°ã©ãã§ããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ æŽ»æ§é µçŽ å€æ§å€ã®ååšã«ããæŽ»æ§ãå€åãã
æå®éã®é µçŽ ãè©²é µçŽ ã«ããåå¿çæç©ã«è»¢æã
ããã®ã«é©ããåºè³ªãè©²é µçŽ ã«ãã該åºè³ªã®è»¢æ
ã«å¿ èŠãªã³ã»ãã¢ã¯ã¿ãŒåã³è©²ã³ã»ãã¢ã¯ã¿ãŒã
åçããããã®ç©è³ªãå«ãã§æãã該åºè³ªãæå®
éååšããããšãç¹åŸŽãšããã詊æäžã®æŽ»æ§é µçŽ
倿§å€ã®ååŠåã¯éãæž¬å®ããããã®çµæç©ã ïŒ æŽ»æ§é µçŽ å€æ§å€ã®ååšã«ããæŽ»æ§ãå€åãã
æå®éã®é µçŽ ãè©²é µçŽ ã«ããåå¿çæç©ã«è»¢æã
ããã®ã«é©ããåºè³ªãè©²é µçŽ ã«ãã該åºè³ªã®è»¢æ
ã«å¿ èŠãªã³ã»ãã¢ã¯ã¿ãŒãåã³è©²åºè³ªãåçãã
ããã®ç©è³ªãå«ãã§æãã該ã³ã»ãã¢ã¯ã¿ãŒãæ
å®éååšããããšãç¹åŸŽãšããã詊æäžã®æŽ»æ§é µ
çŽ å€æ§å€ã®ååŠåã¯éãæž¬å®ããããã®çµæç©ã ïŒ æŽ»æ§é µçŽ å€æ§å€ã®ååšã«ããæŽ»æ§ãå€åãã
æå®éã®é µçŽ ãè©²é µçŽ ã«ããåå¿çæç©ã«è»¢æã
ããã®ã«é©ããåºè³ªãè©²é µçŽ ã«ãã該åºè³ªã®è»¢æ
ã«å¿ èŠãªã³ã»ãã¢ã¯ã¿ãŒã該åºè³ªãåçãããã
ã®ç©è³ªãåã³è©²ã³ã»ãã¢ã¯ã¿ãŒãåçããããã®
ç©è³ªãå«ãã§æãã詊æäžã®æŽ»æ§é µçŽ å€æ§å€ã®å
åŠåã¯éãæž¬å®ããããã®çµæç©ã ïŒ æŽ»æ§é µçŽ å€æ§å€ã®ååšã«ããæŽ»æ§ãå€åãã
æå®éã®é µçŽ ãè©²é µçŽ ã«ãã転æãããã®ã«é©ã
ãåºè³ªåã³è©²é µçŽ ã«ãã該åºè³ªã®åå¿çæç©ãžã®
転æã«å¿ èŠãªã³ã»ãã¢ã¯ã¿ãŒãäžç·ã«ãã該ã³ã»
ãã¢ã¯ã¿ãŒãåçãããã䞊ã³ã«ã詊æäžã®æŽ»æ§
é µçŽ å€æ§å€ã®ååŠåã¯éã®é¢æ°ã§ããè©²é µçŽ ã®æŽ»
æ§ã枬å®ããæ®µéãå«ãã§æã該詊æäžã®è©²æŽ»æ§
é µçŽ å€æ§å€ã®ååŠåã¯éã®æž¬å®æ¹æ³ã ïŒ åèšé µçŽ ã®æŽ»æ§ã枬å®ããæ®µéãæå®ã®åçº
åºè³ªæ¿åºŠã®å€åã®æéããããæž¬å®ãå«ãã§æã
ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æž¬å®æ¹æ³ã ïŒ åèšã³ã»ãã¢ã¯ã¿ãŒãåçããããæ®µéãã
åçã®çµæãšããŠåèšã³ã»ãã¢ã¯ã¿ãŒã®ã»ãã«ä»
ã®æž¬å®å¯èœãªç©è³ªãçæããããããšãå«ãã§æ
ãããããŠåèšé µçŽ ã®æŽ»æ§ã枬å®ããæ®µéãã該
ä»ã®æž¬å®å¯èœãªç©è³ªã®æ¿åºŠã®å€åã®æéãããã
枬å®ãå«ãã§æãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æž¬
宿¹æ³ã ïŒ æŽ»æ§é µçŽ å€æ§å€ã®ååšã«ããæŽ»æ§ãå€åãã
æå®éã®é µçŽ ãè©²é µçŽ ã«ãã転æãããã®ã«é©ã
ãåºè³ªãåã³è©²é µçŽ ã«ãã該åºè³ªã®åå¿çæç©ãž
ã®è»¢æã«å¿ èŠãªã³ã»ãã¢ã¯ã¿ãŒãäžç·ã«ãã該åº
質ãåçãããã䞊ã³ã«ã詊æäžã®æŽ»æ§é µçŽ å€æ§
å€ã®ååŠåã¯éã®é¢æ°ã§ããè©²é µçŽ ã®æŽ»æ§ã枬å®
ããæ®µéãå«ãã§æã該詊æäžã®è©²æŽ»æ§é µçŽ å€æ§
å€ã®ååŠåã¯éã®æž¬å®æ¹æ³ã ïŒ åèšé µçŽ ã®æŽ»æ§ã枬å®ããæ®µéãã³ã»ãã¢ã¯
ã¿ãŒã®æå®ã®åçºæ¿åºŠã®å€åã®æéããããæž¬å®
ãå«ãã§æãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æž¬å®æ¹
æ³ã ïŒ åèšåºè³ªãåçããããæ®µéããåçã®çµæ
ãšããŠåèšåºè³ªã®ã»ãã«ä»ã®æž¬å®å¯èœãªç©è³ªãç
æããããããšãå«ãã§æãããããŠåèšé µçŽ ã®
掻æ§ã枬å®ããææ®µãã該ä»ã®æž¬å®å¯èœãªç©è³ªã®
æ¿åºŠã®å€åã®æéããããæž¬å®ãå«ãã§æãç¹èš±
è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æž¬å®æ¹æ³ã ïŒïŒ 掻æ§é µçŽ å€æ§å€ã®ååšã«ããæŽ»æ§ãå€åã
ãæå®éã®é µçŽ ãè©²é µçŽ ã«ãã転æãããã®ã«é©
ããåºè³ªãåã³è©²é µçŽ ã«ãã該åºè³ªã®åå¿çæç©
ãžã®è»¢æã«å¿ èŠãªã³ã»ãã¢ã¯ã¿ãŒãäžç·ã«ãã該
åºè³ªãåçãããã該ã³ã»ãã¢ã¯ã¿ãŒãåçãã
ãã䞊ã³ã«ã詊æäžã®æŽ»æ§é µçŽ å€æ§å€ã®ååŠåã¯
éã®é¢æ°ã§ããè©²é µçŽ ã®æŽ»æ§ã枬å®ããæ®µéãå«
ãã§æã該詊æäžã®è©²æŽ»æ§é µçŽ å€æ§å€ã®ååŠåã¯
éã®æž¬å®æ¹æ³ã ïŒïŒ åèšã³ã»ãã¢ã¯ã¿ãŒãåçããããæ®µé
ããåçã®çµæãšããŠåèšã³ã»ãã¢ã¯ã¿ãŒã®ã»ã
ã«ä»ã®æž¬å®å¯èœãªç©è³ªãçæããããããšãå«ã
ã§æãããããŠåèšé µçŽ ã®æŽ»æ§ã枬å®ããæ®µé
ãã該ä»ã®æž¬å®å¯èœãªç©è³ªã®æ¿åºŠã®å€åã®æéã
ãããæž¬å®ãå«ãã§æãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒïŒé
èšèŒã®æž¬å®æ¹æ³ã ïŒïŒ åèšåºè³ªãåçããããæ®µéããåçã®çµ
æãšããŠåèšåºè³ªã®ã»ãã«ä»ã®æž¬å®å¯èœãªç©è³ªã
çæããããããšãå«ãã§æãããããŠåèšé µçŽ
ã®æŽ»æ§ã枬å®ããææ®µãã該ä»ã®æž¬å®å¯èœãªç©è³ª
ã®æ¿åºŠã®å€åã®æéããããæž¬å®ãå«ãã§æãç¹
èš±è«æ±ã®ç¯å²ç¬¬ïŒïŒé èšèŒã®æž¬å®æ¹æ³ã ïŒïŒ åèšæŽ»æ§é µçŽ å€æ§å€ããªã¬ã³ãã«çµåããŠ
ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«èšèŒã®çµæç©ã ïŒïŒ åèšæŽ»æ§é µçŽ å€æ§å€ããªã¬ã³ãã«çµåããŠ
ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«èšèŒã®çµæç©ã ïŒïŒ åèšæŽ»æ§é µçŽ å€æ§å€ããªã¬ã³ãã«çµåããŠ
ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«èšèŒã®çµæç©ã ïŒïŒ åèšæŽ»æ§é µçŽ å€æ§å€ããªã¬ã³ãã«çµåããŠ
ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«èšèŒã®æž¬å®æ¹æ³ã ïŒïŒ åèšæŽ»æ§é µçŽ å€æ§å€ããªã¬ã³ãã«çµåããŠ
ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«èšèŒã®æž¬å®æ¹æ³ã ïŒïŒ åèšæŽ»æ§é µçŽ å€æ§å€ããªã¬ã³ãã«çµåããŠ
ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒïŒé ã«èšèŒã®æž¬å®æ¹æ³ã
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39916882A | 1982-07-19 | 1982-07-19 | |
| US399168 | 1982-07-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5966895A JPS5966895A (ja) | 1984-04-16 |
| JPH0443639B2 true JPH0443639B2 (ja) | 1992-07-17 |
Family
ID=23578432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP12958683A Granted JPS5966895A (ja) | 1982-07-19 | 1983-07-18 | 掻æ§é µçŽ å€æ§å€ã®æž¬å®æ¹æ³åã³ãã®ããã®çµæç© |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0099567B1 (ja) |
| JP (1) | JPS5966895A (ja) |
| AU (1) | AU574646B2 (ja) |
| CA (1) | CA1222439A (ja) |
| DE (1) | DE3380698D1 (ja) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4835099A (en) * | 1986-11-20 | 1989-05-30 | Becton, Dickinson And Company | Signal enhancement in immunoassay by modulation of enzymatic catalysis |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4230797A (en) * | 1975-04-28 | 1980-10-28 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a coenzyme as label |
| US4134792A (en) * | 1976-12-06 | 1979-01-16 | Miles Laboratories, Inc. | Specific binding assay with an enzyme modulator as a labeling substance |
| GB1595101A (en) * | 1977-03-15 | 1981-08-05 | Hoffmann La Roche | Enzyme modifier immunoassay |
| IT1105734B (it) * | 1977-07-14 | 1985-11-04 | Syva Co | Prova di legame di competizione di antienzima omogeneo |
| DE2924249C2 (de) * | 1978-06-22 | 1989-04-27 | Miles, Inc., Elkhart, Ind., Us | Spezifische bindungs-untersuchungsmethode zur bestimmung eines liganden in einem fluessigen medium und reagentien zur durchfuehrung dieser methode |
| US4394449A (en) * | 1980-02-13 | 1983-07-19 | Modrovich Ivan Endre | Stabilization of coenzymes in aqueous solution |
| EP0099742A1 (en) * | 1982-07-17 | 1984-02-01 | Grand Metropolitan Biotechnology Ltd. | Enzymatic reaction process |
-
1983
- 1983-07-08 AU AU16666/83A patent/AU574646B2/en not_active Ceased
- 1983-07-18 DE DE8383107042T patent/DE3380698D1/de not_active Expired
- 1983-07-18 JP JP12958683A patent/JPS5966895A/ja active Granted
- 1983-07-18 CA CA000432658A patent/CA1222439A/en not_active Expired
- 1983-07-18 EP EP19830107042 patent/EP0099567B1/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| EP0099567A3 (en) | 1984-05-30 |
| AU1666683A (en) | 1984-01-26 |
| EP0099567A2 (en) | 1984-02-01 |
| JPS5966895A (ja) | 1984-04-16 |
| DE3380698D1 (en) | 1989-11-16 |
| CA1222439A (en) | 1987-06-02 |
| AU574646B2 (en) | 1988-07-14 |
| EP0099567B1 (en) | 1989-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Titheradge | The enzymatic measurement of nitrate and nitrite | |
| EP0330517B2 (en) | Method, system and devices for the assay and detection of biochemical molecules | |
| US5521060A (en) | Use of a sparingly soluable salt of a heteropoly acid for the determination of an analyte, a corresponding method of determination as a suitable agent therefor | |
| US4357420A (en) | Bioluminescence methods for enzymatic determinations | |
| WO1980001081A1 (fr) | Procede analytique et moyen de mesure de la quantite d'eau oxygenee en milieu aqueux et de substrats organiques produisant de l'eau oxygenee par oxydation enzymatique | |
| JP2005517960A (ja) | ïœïœïœåã¯ïœïœïœïœã®é»æ°ååŠçæ€åº | |
| US4120755A (en) | Kinetic method for determination of glucose concentrations with glucose dehydrogenase | |
| US4143080A (en) | Method and reagent for the assay of hydroperoxide | |
| Qin et al. | Energetics of two-step binding of a chromophoric reaction product, trans-3-indoleacryloyl-CoA, to medium-chain acyl-coenzyme-A dehydrogenase | |
| JP2788264B2 (ja) | é µçŽ ã®å®éæ³ããã³ããã«çšããè£ çœ® | |
| JPH0443639B2 (ja) | ||
| US5589349A (en) | Method for enzymatic analysis and reagant therefor | |
| CA2111168A1 (en) | Stable single liquid reagent for the determination of carbon dioxide in serum | |
| IWAI et al. | Electric microassays of glucose, uric acid and cholesterol using peroxidase adsorbed on a carbon electrode | |
| Rui et al. | A flow-injection biosensor system for the amperometric determination of creatinine: simultaneous compensation of endogenous interferents | |
| Kayamori et al. | Enzymatic method for assaying uric acid in serum with a new tetrazolium salt produces water-soluble formazan dye | |
| EP0598620A2 (en) | An analytical system or kit for phosphatase | |
| Yip et al. | Interaction of tetraiodofluorescein with yeast hexokinase. | |
| Kamoun et al. | Ultramicromethod for determination of plasma uric acid. | |
| Tiffany et al. | Feasibility of multiple simultaneous enzyme assays, for diagnostic purposes, with the GeMSAEC fast analyzer | |
| Clarke et al. | Formation of a Tight 1: 1 Complex of Clostridium pasteurianum Fe Proteinâ Azotobacter vinelandii MoFe Protein: Evidence for Long-Range Interactions between the Fe Protein Binding Sites during Catalytic Hydrogen Evolution | |
| Bannister et al. | Development of amperometric biosensors for enzyme immunoassay | |
| EP0398920A1 (en) | Enzyme labelled biochemical assay for two analytes | |
| JP3869601B2 (ja) | ãã¢ã·ã¹ãã€ã³ã®æž¬å®æ¹æ³ | |
| Chen | Redox electrode for monitoring dehydrogenase-catalyzed reactions |